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Background: Continuous-flow (CF) left ventricular assist devices (LVADs) have gained 
widespread clinical acceptance as a treatment option for advanced heart failure (HF); 
however, they have also been associated with an increased risk of adverse events, including 
gastrointestinal bleeding, aortic insufficiency, and hemorrhagic stroke. It has been 
hypothesized that the increase in adverse event incidence may be due in part to diminished 
vascular pulsatility and high shear stress when CF-LVADs are operated at fixed speeds. 
Previous studies have shown that pump speed modulation generates greater levels of 
pulsatility in rotary pumps than when operated at fixed speeds. The objective of this study 
was to characterize the hemodynamic and pump performance of LVADs operated with a 
low-frequency asynchronous pump speed modulation algorithm in a chronic healthy 
bovine model with partial VAD support. 
Materials and Methods: Clinical-grade LVAD with aortic (HeartWare HVAD, n=3) or 
transaortic (proprietary VADx, n=4) outflow were implanted into chronic (30-day) healthy 
male Jersey calves (60-110 kg). An asynchronous pump speed modulation algorithm 
(frequency = 20 bpm, amplitude = 2500-4000 RPM for HVAD or 11000-19000 RPM for 
VADx) was implemented by controlling pump current. Hemodynamic measurements 
(pressures, flows) were recorded throughout the study duration (30s epochs collected 
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hourly at 400Hz), echocardiographic data was recorded during the implant, weekly, and at 
terminal, and blood laboratory measurements were regularly collected throughout the 
study. All data were analyzed to characterize aortic pulsatility, LV unloading, blood 
damage, and device power usage. Statistical analysis was performed to determine 
significance between fixed and pump speed modulation operating conditions. 
Results and Discussion: Two HVAD and four VADx animals achieved the 30-day study 
endpoint. Due to surgical complications, one animal died intraoperatively. Both HVAD 
devices maintained asynchronous modulation for the full study duration with mean high 
and low speeds of 4000 RPM and 2500 RPM, respectively. Two of the four VADx devices 
maintained asynchronous modulation at average high and low speeds of 17238 RPM and 
11333 RPM over the 30-day study; however, the other two VADx devices operated at fixed 
pump speed for 1 and 2 days, respectively, due to unforeseen controller malfunctions, 
which were corrected to restore asynchronous modulation. Near-physiologic aortic pulse 
pressure for HVAD (45±4 mmHg) and VADx (46±9 mmHg) was demonstrated. HVAD 
and VADx with asynchronous modulation reduced stroke volume by 27% and 23%, 
respectively. HVAD (n=2) and VADx (n=3) maintained plasma free hemoglobin (pfHb) 
less than 40 mg/dL for the entire study duration while one VADx had pfHb > 40 mg/dL 
for a period of 3 days, which resolved. Asynchronous modulation increased power 
consumption with HVAD (25%) and VADx (6%) compared to fixed speed operation. 
Conclusion: This study demonstrated asynchronous modulation of HVAD and VADx 
maintained near-physiologic pulsatility and LV unloading at the expense of minimal 
hemolysis and increased power consumption in the partial VAD support model. Future 
studies in clinically-relevant heart failure models warrant further investigation. 
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A. Cardiovascular Physiology: A Healthy Heart 
        A normal human heart is comprised of 4 chambers which allows the complete 
separation of the deoxygenated and oxygenated blood increasing the efficiency of nutrient 
exchange in the circulation. Deoxygenated blood returns from the systemic circulation 
through the superior and inferior vena cava and enters the right atrium (RA) and then the 
right ventricle (RV) through the tricuspid valve. It then leaves the RV through the 
pulmonary valve and pulmonary artery and travels through the pulmonary circulation 
where it become oxygenated and returns to the heart via the pulmonary veins. The 
pulmonary veins empty into the left atrium (LA), and the oxygenated blood enters the left 
ventricle (LV) through the mitral valve. Blood is ejected from the LV and crosses the aortic 
valve and flows through the aorta and the systemic circulation. An illustration summarizing 
the complete systemic and pulmonary circulations is shown in Figure 1. 
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FIGURE 1: The path of blood flow through the heart. Blood flow begins with the pulmonary 
circulation (blue) to oxygenate blood which is returned to the LA and pumped into the systemic 
circulation (red). Blood flow direction is depicted by white arrows. 
       A cardiac cycle consists of periods of low pressure (diastole) and high pressure 
(systole). During diastole the heart muscle relaxes from its contracted systolic state, blood 
flows from the atria into the ventricles, and pressure builds in the heart due to the increasing 
volume (preload). The end of diastole occurs when the atria contract and empty the 
remaining blood volume into the ventricles. Systole occurs directly after when the 
ventricles begin to isometrically contract increasing ventricular pressure until it is greater 
than the pressure in the corresponding circulations (afterload). At this point, the pulmonary 
and aortic valves are forced open and blood is ejected from the ventricles into the 
circulations. Relaxation and diastole immediately follow, and the cardiac cycle resumes. 
        Typical hemodynamic waveforms for a healthy heart can be seen in Figure 2. Aortic 
pressure (AoP) reaches about 120 mmHg during systole and falls to around 80 mmHg 
during diastole. Left ventricular pressure (LVP) is around 5 mmHg during diastole and 
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increases slightly as the ventricle fills with blood. During isovolumic contraction, LVP 
increases to the diastolic AoP and then blood is ejected with LVP reaching about 120 
mmHg. Left ventricular volume (LVV) usually increases from 50 mL at the end of systole 
to about 120 mL at the end of diastole. Therefore, the amount of blood ejected from the 
heart in one cardiac cycle (stroke volume; SV) is about 70 mL which makes the amount of 
blood pumped by the heart per minute (cardiac output; CO) typically about 4-8 L/min 
(Kemp & Conte, 2012).  
 
 
FIGURE 2: Hemodynamic waveforms recorded in a mock circulatory loop tuned to healthy 
heart conditions. In a healthy heart, aortic pressure is around 120 mmHg during systole and 80 
mmHg during diastole. LVP is about 5 mmHg during diastole and reaches about 120 mmHg during 
contraction and systole. A typical normal SV and CO is about 70 mL and 4-8 L/min, respectively. 
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        Regulation of the heart contraction is controlled by the rate of venous return and the 
effects of the autonomic nervous system on the myocardium. Sympathetic stimulation 
serves to increase the force of contraction of the heart muscle to as much as double the 
normal effort which increases the SV and the blood’s ejection pressure from the ventricle, 
effectively increasing CO (Hall & Guyton, 2011). Inhibition of the sympathetic stimulation 
results in reduction of cardiac output by decreasing the strength of ventricular contraction 
and the heart rate (HR). Parasympathetic stimulation via the vagus nerve mainly serves to 
decrease the HR while also reducing the strength of the myocardial contraction, effectively 
decreasing CO (Hall & Guyton, 2011). 
        While the autonomic nervous system can control the contractile force and the rate of 
contraction of the heart muscle to affect CO, the main determinant of CO is the rate of 
venous return of blood into the atria and ventricles (Hall & Guyton, 2011). The heart 
possesses an intrinsic ability to respond to increasing volumes of venous return. It 
efficiently pumps all blood that returns to it from the veins within physiological limits, and 
this phenomenon is known as the Frank-Starling mechanism. A graphical representation of 
this phenomenon can be seen in Figure 3. With increasing venous return, the end-diastolic 
volume (LVEDV) of the LV increases and stretches the myocardium increasing end-
diastolic pressure (LVEDP) and the tension between the underlying actin and myosin 
filaments which provides for a greater force during muscle contraction. The increase in the 
contractile force causes a nonlinear increase in SV and CO. 
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FIGURE 3: The Frank-Starling mechanism as represented by three conditions: A) normal 
healthy heart, B) increased myocardial contractility, C) dysfunction of the heart such as in 
heart failure (HF). As preload increases, cardiac output increases nonlinearly until the heart can 
no longer compensate for the additional blood volume. When the heart experiences increased 
contractility, cardiac output increases more for the same increase in preload compared to normal 
function. During heart failure, the heart is unable to efficiently eject blood and can no longer 
adequately compensate for increases in preload. 
       Mean arterial pressure (MAP) is the afterload which the heart must contract against to 
eject blood and is a product of the CO and the total peripheral resistance (TPR) of the 
vasculature. An increase in afterload lowers the efficiency of ventricular contractility and 
shifts the Frank-Starling curve down and to the right. The renin-angiotensin-aldosterone 
system (RAAS) is important in regulating vascular resistance and blood volume by its 
downstream effects of vasoconstriction and salt and fluid retention (Klabunde, 2012). 
When patients develop HF, the overstimulation of the Frank-Starling mechanism and the 
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RAAS can cause a decrease in CO and SV leading to a cycle which results in a decreased 
MAP and worsening of HF symptoms. 
B. Heart Failure Physiology 
1. Symptoms and Classification 
        Over 22 million people are currently estimated to be living with heart failure 
worldwide, and the U.S. prevalence is expected to rise to 3% or over 8 million people by 
2030 (Heidenreich et al., 2013). Heart failure can be defined as the heart’s inability to meet 
the metabolic needs and oxygenation requirements of the body due to an inadequate 
maintenance of CO (Kemp & Conte, 2012; Tanai & Frantz, 2015). Due to the heart’s 
inability to properly eject all blood which enters the ventricles, blood volume can build in 
the pulmonary capillary bed during heart failure increasing pressure and leading to 
symptoms of pulmonary congestion such as dyspnea, cough, and wheezing (Kemp & 
Conte, 2012; Tanai & Frantz, 2015). Renal dysfunction can result from venous congestion 
and/or hypoperfusion during heart failure and can lead to malabsorption and cardiac 
cachexia with the loss of body tissue (Pearse & Cowie, 2014; Tanai & Frantz, 2015). 
Fatigue, palpitations, and nausea can also occur due patients’ low CO, and patients can 
develop anemia which can be worsened by their renal dysfunction (Kemp & Conte, 2012; 
Pearse & Cowie, 2014; Tanai & Frantz, 2015). 
        Heart failure is a progressive disease that can be characterized by the affected ventricle 
(left- or right-sided) or the impaired portion of the cardiac cycle (systolic or diastolic). Left-
sided heart failure is caused by left ventricular dysfunction, and right-sided heart failure is 
a weakening of the right ventricle which often occurs due to fluid backup in the lungs 
caused by left-sided heart failure. Systolic heart failure results from impaired left 
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ventricular contractility and is referred to as heart failure with reduced ejection fraction 
(HF-REF) that is diagnosed with an EF less than 40% (Pearse & Cowie, 2014; Tanai & 
Frantz, 2015). If patients present with heart failure symptoms but have an EF between 40-
50%, this is referred to as heart failure with preserved ejection fraction (Pearse & Cowie, 
2014; Tanai & Frantz, 2015). Chronic heart failure patients develop worsening symptoms 
over time, while acute heart failure is characterized by a more rapid onset of cardiac 
dysfunction and clinical symptoms such as congestion, renal dysfunction, and low cardiac 
output (Krum & Abraham, 2009; Metra & Teerlink, 2017). 
        The New York Heart Association (NYHA) has classified the progression of heart 
failure based on the patient’s clinical condition (Apostolakis & Akinosoglou, 2007; Kemp 
& Conte, 2012). Class I HF represents patients who present no symptoms. Class II HF 
patients are comfortable at rest while having slight limitation in physical activity due to HF 
symptoms, and Class III patients present HF symptoms with mild physical activity while 
being comfortable at rest. Finally, Class IV patients are unable to perform any physical 
activity without HF symptoms emerging. Similarly, the American Heart Association 
(AHA) has classified the disease’s progression, however their distinctions dwell on the 
structural abnormality of the heart (Kemp & Conte, 2012). Patients who are at high risk for 
HF but do not present any symptoms or structural disorders are said to be in Stage A HF. 
Those that present with structural abnormalities but no HF symptoms are in Stage B HF, 
and Stage C HF patients display symptoms of HF and have structural abnormalities. 
Finally, patients in Stage D are said to be in end-stage conditions and require specialized 
interventions and treatment strategies. AHA and NYHA classifications can both be utilized 
and have some overlap in that Stage B corresponds to Class I, Stage C corresponds to Class 
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II and II, and Stage D corresponds to Class IV, while Stage A has no corresponding NYHA 
classification (Kemp & Conte, 2012; Mazurek & Jessup, 2015). 
TABLE I 
CLASSIFICATIONS OF HEART FAILURE AND THEIR DESCRIPTIONS 
AHA Stages of HF Equivalent NYHA Functional Classification 
A – At high risk for HF but has no 
symptoms or structural disorders 
None 
B – No symptoms of HF but has some 
structural cardiac abnormalities 
Class I – No limitation of physical activity and 
ordinary activity does not cause breathlessness or 
fatigue. 
C – Displays symptoms of HF and has 
structural abnormalities 
Class I – No limitation of physical activity and 
ordinary activity does not cause breathlessness or 
fatigue. 
Class II – Slight limitation of physical activity. No 
symptoms while at rest. Ordinary physical activity 
results in symptoms of HF. 
Class III – Marked limitation of physical activity. 
No symptoms while at rest. Less than ordinary 
activity results in HF symptoms. 
Class IV – Unable to carry on any physical activity 
without discomfort. Can have HF symptoms at rest. 
D – Refractory HF requiring specialized 
interventions and treatment strategies 
Class IV – Unable to carry on any physical activity 
without discomfort. Can have HF symptoms at rest. 
 
2. Etiology 
        Since HF can be classified in many different ways, the underlying causes of the 
disease can vary greatly in patients. HF often advances from intrinsic abnormalities in 
myocardial structure and function which have been termed cardiomyopathies (Mazurek & 
Jessup, 2015). The most common cause of cardiomyopathies and HF is coronary artery 
disease (CAD) (Mazurek & Jessup, 2015; Pearse & Cowie, 2014). Ischemic 
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cardiomyopathies (ICM) resulting from a restriction of blood supply to the cardiac tissue 
such as from CAD, myocardial infarction, and toxins such as alcohol are more common in 
the developed world (Pearse & Cowie, 2014; Tanai & Frantz, 2015). Hypertension and 
valvular diseases such as stenosis or insufficiency are also common, however their 
significance has decreased with improved clinical management (Pearse & Cowie, 2014). 
Nonischemic cardiomyopathies (NICM) such as dilated cardiomyopathy (DCM) or 
hypertrophic cardiomyopathy (HCM) are less common and may be the result of genetic 
inheritance (Mazurek & Jessup, 2015). Other clinical conditions that are independent risk 
factors for HF are diabetes, obesity, smoking, cardiac arrhythmias, and congenital heart 
defects (Tanai & Frantz, 2015). 
3. Pathophysiology 
        The development of heart failure is generally regarded to begin with an index event 
such as an abrupt myocardial infarction or prolonged myocardial ischemia that leads to 
activation of compensatory mechanisms that work to maintain MAP, CO, and adequate 
peripheral perfusion (Mazurek & Jessup, 2015; Pearse & Cowie, 2014). Compensatory 
mechanisms that are activated by the index event include ventricular remodeling, activation 
of the RAAS, and the Frank-Starling mechanism (Kemp & Conte, 2012). The prolonged 
activation of these mechanisms eventually begins to have detrimental effects on cardiac 
function and leads to the development of HF. 
        The Frank-Starling mechanism has a greater role in the initial compensatory response 
to a reduced CO. Increasing amounts of preload result in smaller increases in CO as the 
contractile limits of the heart are reached. In HF, a given increase in preload results in a 
smaller increase in CO compared to a healthy heart due to the diminished contractility. As 
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a patient’s HF symptoms worsen with increased preload, the response in CO decreases 
further, and this compensatory mechanism eventually reaches its limits resulting in 
pulmonary congestion and reduced CO (Kemp & Conte, 2012). The result of this effect 
can be seen in Figure 4 as the pressure-volume (PV) loop shifts to the right as preload 
increases. LV end-diastolic pressure (EDP) increases, and end-systolic pressure (EDP) 
decreases which reduces stroke work (SW; area under curve).  
 
FIGURE 4: Effects on PV relationship due to HF. During heart failure, preload increases as the 
heart can no longer efficiently eject blood. This leads to rightward shift (red to blue) of the PV loop  
which also reduces in size due to decreased contractility. ESV: end-systolic volume; EDV: end-
diastolic volume; ESP: end-systolic pressure; EDP: end-diastolic pressure; SV: stroke volume. 
              Ultimately, stimulation of these mechanisms for lengthy periods of time cause a 
positive feedback loop to develop. The diminishing returns of the Frank-Starling 
mechanism with very high levels of preload result in severely reduced CO leading to 
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extended activation of the RAAS eventually resulting in myocardial fibrosis and 
ventricular remodeling such as dilation and thinning of the ventricular wall and septum. 
The ventricular remodeling results in a worsening myocardial function and performance in 
turn decreasing the effectiveness of the Frank-Starling mechanism further. Thus, the 
disease progresses, and patients’ clinical conditions worsen. 
C. Heart Failure Therapy 
1. Pharmacological Management 
        NYHA Class II patients are primarily treated by the use of oral cardiovascular 
medication such as β-blockers and drugs which block the effects of aldosterone (Gilbert & 
Xu, 2017). ACE Inhibitors (ACEIs) were one of the first pharmacological treatments which 
improved mortality and symptoms in HF-REF patients (Krum & Teerlink, 2011; Mazurek 
& Jessup, 2015). ACEIs block the conversion of angiotensin I to angiotensin II and prevent 
the downstream release of aldosterone thereby promoting blood vessels to dilate and 
reducing blood pressure. Angiotensin receptor blockers (ARB) prevent aldosterone release 
by directly blocking angiotensin II from binding to its receptor. ARBs are used less often 
than ACEIs and are mainly indicated for use when ACEIs are not well tolerated (Yancy et 
al., 2013). Aldosterone antagonists or mineralocorticoid receptor antagonists (MRA) may 
be used if ACEIs/ARBs administration is shown to be ineffective. MRAs block the effect 
of aldosterone at its receptor and were found to reduce the risk of death and hospitalization 
in patients treated with standard HF therapy of ACEIs/ARBs and β-blockers (Zannad et 
al., 2011). β-blockers prevent the binding of norepinephrine and epinephrine to the major 
classes of β adrenergic receptors (β-ARs: β1, β2) and therefore decrease contractility and 
heart rate which helps to manage high blood pressure, angina, and arrhythmias. In a meta-
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analysis of all randomized, controlled clinical trials investigating β-blockers, Al-Gobari et 
al found that β-blockers reduce the risk of death by 33% and the risk of sudden cardiac 
death (SCD) by 31% (Al-Gobari et al., 2013). For patients experiencing congestion and 
volume overload, diuretics may be used to reduce preload and relieve symptoms (Krum & 
Abraham, 2009). 
2. Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy 
        Additional interventions may be needed for patients who are deemed to be in Stage C 
heart failure (NYHA Class II, III, IV) and diagnosed with HF-REF. These patients have an 
increased risk for SCD and ventricular arrhythmias and may undergo placement of an 
implantable cardioverter defibrillator (ICD) for arrhythmia monitoring and correction 
(Mazurek & Jessup, 2015). In addition, patients who have experienced incidents of 
ventricular fibrillation or ventricular tachycardia may undergo ICD implant for secondary 
prevention of SCD (McMurray, 2010). ICDs are implanted within the chest and are 
connected to the heart via electrical leads. The devices work to detect abnormal heart 
rhythms and send an electrical shock to the heart to restore a normal heartbeat. A meta-
analysis of 14 different randomized, controlled trials and longitudinal, nonrandomized, 
comparative studies investigating the benefit of ICDs showed a decrease in the incidence 
of SCD and all-cause mortality due to ICD use (Earley et al., 2014). 
        Biventricular pacemakers are similar to ICDs and are also connected to the heart via 
electrical leads. These devices are used to provide cardiac resynchronization therapy (CRT) 
to treat ventricular dyssynchrony by monitoring and controlling the HR with electrical 
stimulation. They have been shown to immediately improve cardiac performance, reduce 
mitral regurgitation caused by the dyssynchrony, and increase the SV (Dickstein et al., 
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2008; Hunt et al., 2009). This therapy has been shown to be more beneficial in NYHA 
Class I and II patients with widened QRS intervals than in Class III patients with narrowed 
QRS intervals (McMurray, 2010). 
3. Mechanical Circulatory Support 
         NYHA Class III and IV patients whose HF symptoms continue to worsen despite 
medical therapy may require advanced clinical interventions. Mechanical circulatory 
support (MCS) has become increasingly used to treat and manage these patients due to the 
limited number of donor hearts available for HT. MCS devices may be used to restore 
myocardial performance (bridge-to-recovery; BTR), support patients until a donor heart 
can be procured (bridge-to-transplant; BTT), or for primary relief of HF symptoms without 
the goal of heart transplant (HT) or device removal (destination therapy; DT). The number 
of adult HT recipients who were previously treated with MCS devices has increased in the 
past decade and is about 40% (Andrew & Macdonald, 2015; Hullin, 2014). 
4. Heart Transplant 
        Dr. Christiaan Barnard performed the first human to human heart transplant in South 
Africa in 1967. However, the procedure was not widely adopted until the 1980s when 
immunosuppression drugs were introduced that improved transplant outcomes. In a HT 
procedure, a donor heart is secured from an organ donor who has been determined to have 
similar biological profile to the recipient. The failing heart is removed from the recipient 
at the great vessels which are then attached to the donor heart. According to the ACC/AHA 
guidelines, HT is indicated for patients with NYHA class III or IV HF despite continued 
medical therapy, MCS use, and surgical management (Yancy et al., 2013). Comorbidities 
such as irreversible renal failure, liver disease, pulmonary disease, and pulmonary artery 
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hypertension may be contraindications for HT if a physician believed the conditions would 
not improve after HT (Hullin, 2014; Yancy et al., 2013). While HT is considered the best-
in-care for end-stage HF patients, complications are still common despite a 5-year survival 
rate of 70% (Alraies & Eckman, 2014). Graft failure is the leading cause of death in the 
first 30 days after transplant, and infection is the most prevalent complication in the first 
year after transplant (Lund et al., 2017). 
D. Types of Mechanical Circulatory Support 
        MCS use has become increasingly more common in order to relieve HF symptoms 
and alleviate the growing wait list for HT. MCS systems can be categorized based on 
duration of care with short term devices including those used primarily in patients 
experiencing cardiogenic shock and long-term devices serving as more dedicated 
circulatory support. 
        Short-term, temporary MCS devices are primarily used to decrease preload and 
afterload and enhance CO in patients experiencing cardiogenic shock such as from 
myocardial infarction and in patients undergoing high risk cardiac interventions such as 
percutaneous coronary interventions and trans-catheter aortic valve implantations (Ferrari 
et al., 2015; Gilotra & Stevens, 2014). Intra-aortic balloon pumps (IABPs) are used to 
provide MCS during cardiogenic shock, during high risk procedures, and as a bridge to 
cardiac surgery. The balloon is placed in the descending aorta usually via the femoral artery 
and is inflated during diastole then deflated during systole creating a counterpulsation 
pumping mechanism. This counterpulsation works to enhance LV unloading, decrease 
preload and afterload, and improve coronary perfusion (Gilotra & Stevens, 2014). The 
Impella (ABIOMED, Danvers, MA) family of various sized percutaneous ventricular assist 
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devices (VAD) is an alternative to IABPs for use in high risk cardiac interventions and 
during cardiogenic shock. The Impella is implanted similar to IABPs through the femoral 
artery, but its motor assemblies are placed retrograde across the aortic valve into the LV 
and left in place typically up to 5 days (Sarkar & Kini, 2010). The Impella provides patient 
support and LV unloading by continuously pumping blood from the LV into the systemic 
circulation independent of LV contraction and heart rate. 
        Extracorporeal membrane oxygenation (ECMO) is a form of MCS for HF patients 
who require acute cardiac support for longer periods than IABPs or Impella devices can 
provide. In addition, for patients who require respiratory support, ECMO can be utilized to 
externally oxygenate blood and return it to the circulation. Venovenous (VV) ECMO is 
used to provide support for patients experiencing respiratory failure. This ECMO circuit 
removes deoxygenated blood from the inferior vena cava and returns oxygenated blood to 
the right heart through cannulas placed in the right femoral vein and right jugular vein 
respectively. For patients who require hemodynamic support in addition to gas exchange, 
venoarterial (VA) ECMO removes deoxygenated blood from the inferior vena cava and 
returns retrograde oxygenated blood flow to the aorta. VA ECMO is used to primarily 
bridge patients to longer term support such as left ventricular assist devices (LVADs) or 
HT (Gilotra & Stevens, 2014). 
        Long term MCS for HF patients is provided by the use of VADs or total artificial 
hearts (TAHs). VADs work to support cardiac output and end-organ perfusion by reducing 
the myocardial workload. These devices can be used to support the function of both the 
right (RVADs) and left ventricles (LVADs), however systemic circulatory support is their 
primary use case. Figure 5 shows the effect that VADs have on the HF PV loop as they 
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reduce myocardial work and unload the failing ventricle. First generation VADs such as 
the Thoratec PVAD (Abbott, Chicago, IL) used an internal membrane to displace blood 
volume by utilizing large external pneumatic drivers and creating pulsatile blood flow (PF). 
Second generation devices such as the HeartMate II (Abbott) were developed to be smaller 
and more easily implanted and used internal impellers which deliver continuous blood flow 
(CF). Current third generation devices such as the HVAD (HeartWare / Medtronic, 
Framingham, MA) continue to provide CF support, however the internal impeller is 
levitated by hydrodynamic or magnetic forces which minimizes thrombosis and bearing 
failure. 
 
FIGURE 5: Effects on PV relationship due to VAD support. Preload decreases as the ventricle 
is further unloaded, therefore the PV loop shifts back to the left (blue to dashed line) as the VAD 
reduces ventricular volumes. The PV loop becomes even smaller due to the reduction in stroke 
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work as the VAD reduces the myocardial workload. ESV: end-systolic volume; EDV: end-diastolic 
volume; ESP: end-systolic pressure; EDP: end-diastolic pressure; SV: stroke volume. 
        While the use of VADs has become increasingly popular to treat late stage HF 
patients, some of those patients may be too sick to actually benefit from VAD support. 
However, those patients need to be treated before a HT becomes viable, so a TAH is used 
to replace their failing heart with a system that can maintain perfusion for the pulmonary 
and systemic circulations at once. TAHs are implanted by removing the native heart at the 
atria and sewing the device’s atrial cuffs to the remaining atrial tissue. The AbioCor 
Implantable Replacement Heart (IRH; ABIOMED) was used as an alternative to HT for 
DT, however it is no longer in clinical use due to high costs and poor outcomes (Ferrari et 
al., 2015). The SynCardia TAH (TAH-t; Syncardia, Tucson, AZ), formerly known as the 
CardioWest TAH, is in clinical use for BTT therapy and is currently the only commercially 
available TAH. In a multicenter study examining the safety and efficacy of the TAH-t in 
patients eligible for HT with irreversible biventricular failure, 79% of patients survived to 
transplant compared to only 46% of control patients without a TAH-t implanted (Copeland 
et al., 2004). In addition, the TAH-t was shown to improve the survival rate post-
transplantation with a one-year survival rate of 70% for TAH-t patients compared to only 
31% for control patients. 
E. Clinical Challenges of VAD Support 
        While VADs have become increasingly beneficial in treating HF patients and 
reducing the number of patients urgently needing a HT, their use is not without clinical 
complications. Suction events, right ventricular (RV) failure, bleeding and thrombotic 
events, infection, and valvular disease are some of the post-implant complications which 
have been associated with VAD use (Ensminger et al., 2016). 
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        RV failure is one of the primary concerns post-VAD implant as it is a significant risk 
factor for mortality occurring in 10-40% of LVAD patients (Lampert & Teuteberg, 2015). 
When the RV becomes overloaded with volume compared to the LV, LV filling pressure 
and volume can decrease and cause a reduction in CO. With increasing decompression of 
the LV as VAD speed and LV unloading increases, the interventricular septum begins to 
experience a leftward shift as the septum is pulled towards the LV (A. H. Goldstein et al., 
2005). This shift causes the RV to dilate and hinders the septal contribution to RV ejection 
which can induce right heart dysfunction. RV failure can be treated by lowering VAD 
speeds until an adequate LV volume can be achieved which can help to reverse the septal 
shift, or an RVAD can be implanted creating a BiVAD support system where both 
circulations are perfused by MCS (Potapov et al., 2011; Toda & Sawa, 2015). In addition, 
RV failure can lead to ventricular arrhythmias which can cause thrombotic events; 
subsequently, patients should be considered for ICD implant if not previously performed 
(Potapov et al., 2011). 
        Infections due to VAD implant are common (13.6 events/100 patient months in first 
3 months post-implant) and can manifest at the pump’s drive line tunneling site, in the 
pump’s pericardial pocket, and at the outflow graft and apical sewing ring anastomosis 
which can lead to development of LV endocarditis (Kirklin et al., 2017). If treatment with 
antibiotics fails to resolve infections, a device replacement or even HT may be the only 
option (Potapov et al., 2011; Toda & Sawa, 2015). Valvular diseases such as mitral stenosis 
(MS), mitral regurgitation (MR), aortic insufficiency (AI), and animation problems of the 
aortic valve, including aortic valve fusion and supra-aortic blood stasis, can occur in VAD 
patients and are usually treated with valve replacement or by surgically closing the valve 
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(Adamson et al., 2011). AI can lead to a decreased end-organ perfusion and a reduction in 
cardiac output if not corrected and may indicate potentially unsuccessful long-term VAD 
treatment (Potapov et al., 2011). 
        VAD patients are at an increased risk for bleeding complications post-implant due to 
the required anticoagulation needed to reduce the chance of pump thrombosis. Bleeding 
complications have been observed to have a higher incidence in CF-VAD patients, and this 
has been suggested to be due higher shear stress on blood leading to acquired von 
Willebrand syndrome (Barić, 2014; Ensminger et al., 2016; Greenwood & Herr, 2014). 
Despite anticoagulation therapy, patients may still experience pump thrombosis events, and 
the incidence of thrombosis has been observed to be increased with the use of CF rotary 
pumps compared to pulsatile devices (D. J. Goldstein et al., 2013). However, the increased 
incidence may be due to longer support periods that are common with CF-VADs compared 
to PF-VADs (Ensminger et al., 2016). 
        These findings have introduced a debate revolving around the need for a physiologic 
pulse and if these conditions are due to the lack of pulsatile flow. Early studies found that 
pulsatile flow and pulse pressure was responsible for maintenance of capillary structure, 
fluid balance, and nutrient exchange (Prior et al., 1995; Takeda, 1960). Bartoli et al showed 
that pulsatile unloading of the LV in a heart failure bovine model preserved myocardial 
and vascular energy more than continuous unloading (Bartoli et al., 2010). Studies have 
found that AI may be linked to a lack of aortic valve opening, and it has been proposed that 
CF devices prevent the aortic valve from opening during high support because of increased 
strain on the valve leaflets (Cowger et al., 2010; Hatano et al., 2011; May-Newman et al., 
2010). However, Potapov et al could not identify relevant differences between continuous 
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and pulsatile flow profiles in arterial wall characteristics of clinical samples and concluded 
that long-term CF-VAD use did not adversely affect vascular wall properties (Potapov et 
al., 2012). Additionally, Radovancevic et al compared end-organ function in patients on 
long-term VAD support and concluded based on their data that both CF-VADs and PF-
VADs provided adequate end organ perfusion (Radovancevic et al., 2007). Therefore, there 
is no clear conclusion about the long-term effects of CF-VAD use. Yet, the growing 
amount of evidence suggesting that these unwanted changes in cardiac physiology may be 
stimulated by the lack of a physiological pulse has prompted the development of pump 
speed modulation algorithm with CF devices to provide a more physiologic PF profile. 
F. Pseudo-Pulsatile Flow 
        Various efforts have been made into modifying device operational characteristics of 
current generation devices to induce pulsatile flow, however these modifications can only 
achieve a quasi-pulsatile flow instead of true pulsatility due to the always-on nature of the 
internal impeller. Clinicians have primarily resorted to reducing the speed of CF devices 
which promotes aortic valve opening, reducing the chance of AI, and allows the heart to 
promote natural pulsatility by having a greater share of the systemic flow (Bartoli & Atluri, 
2015). However, Yang et al tested a transparent replica of a HeartMate II device in a mock 
circulatory loop and found that operating CF devices in these “pulsatile” conditions can 
increase turbulent flow within the pumps (Yang et al., 2015). It was suggested that the 
recent increase in pump thrombosis incidents could be at least partially attributed to the 
trend of reduced speed CF-VAD use. Therefore, operating these devices at lower speeds is 
not the complete answer to inducing pulsatile flow, and it has been proposed that CF-VADs 
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can be programmed to produce near physiologic pulsatility and volume unloading by 
modulating pump speed (Barić, 2014; Moazami et al., 2015).  
        One of the earliest studies performed on this topic was Bearnson et al in 1996 who 
found it was possible to operate a CF device in a pulsatile fashion using a computer model 
controlling a centrifugal prototype pump in a mock circulatory loop (Bearnson et al., 1996). 
In an ovine model, Bourque et al in 2006 operated the HeartMate III (Abbott) in a pulsatile 
fashion by alternating between high and low speed at a rate of 60 bpm which resulted in a 
pulse pressure of 30 mmHg, yet their quantification of pulsatility did not improve from CF 
operation (Bourque et al., 2006). More recently, research into strategies to induce 
pulsatility has focused on synchronizing speed modulation with the cardiac cycle. 
Pirbodaghi et al showed that in an ovine model synchronized pulsing provided greater 
pulsatile and physiologic hemodynamics compared to CF (Pirbodaghi et al., 2012). 
        In addition, various timing strategies for synchronized pulsing such as co-pulsation 
and counter-pulsation have been developed to investigate potential benefits from different 
modulation profiles. Co-pulse operation is when the VAD’s high speed period occurs 
during systole and its low speed period occurs during diastole, and the reverse is true for 
counter-pulse operation. Studies comparing these two strategies have concluded that 
counter-pulsation increases ventricular unloading while decreasing pulse pressure and 
myocardial oxygen demand and that co-pulsation increases pulse pressure and myocardial 
oxygen demand while decreasing ventricular unloading (Moazami et al., 2015; Shi et al., 
2010; Umeki et al., 2012; Umeki, Nishimura, Ando, et al., 2013; Umeki, Nishimura, 
Takewa, et al., 2013). Ising et al used a computational model to test over 150 different 
speed modulation algorithms and found that asynchronous modulation significantly 
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increased energy equivalent pressure (EEP) and surplus hemodynamic energy (SHE), 
which are measures of pulsatility, compared to synchronous algorithms (Ising et al., 2011). 
The same conclusion was reached by Soucy et al who compared co-pulse, counter-pulse, 
and asynchronous CF-VAD operation in an ischemic heart failure bovine model (Soucy et 
al., 2015).  It was demonstrated that counter-pulsation reduced LV external work (LVEW) 
and provided the best support for relieving stress from a failing heart and that co-pulsation 
generated greater pulsatility while providing the best hemodynamic support in ischemic 
heart failure animals. However, Soucy et al. concluded that asynchronous modulation 
demonstrated a greater potential to restore pulsatility compared to synchronous operation, 
and this could be potentially attributed to intermittent periods of co-pulse and counter-pulse 
support. Asynchronous modulation also possesses the inherent benefit of not requiring a 
trigger signal to synchronize the device’s rotor to the heartbeat which greatly simplifies its 
implementation in VADs compared to co-pulse or counter-pulse mechanisms. 
G. Technology Overview 
        Currently, there is little information reported on the long-term physiological effects 
of speed modulation. In this study, pump and hemodynamic performance of asynchronous 
modulation were investigated in a chronic healthy bovine model using two CF-VADs 
providing partial cardiac support: the HeartWare HVAD and a proprietary device VADx. 
        The HVAD has a centrifugal flow profile with an impeller that is suspended by 
hydrodynamic and magnetic thrust bearings which prevents impeller contact with the pump 
housing. The device itself is comprised of three primary parts: a front housing with an 
integrated inflow cannula, an internal rotor with a wide-blade impeller, and a rear housing 
with an internal, magnetic center post (LaRose et al., 2010). Both housings contain a motor 
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stator with six copper coils, and the impeller contains four magnets on its perimeter and a 
stack of magnets surrounding its center hole. A magnetic force between the center post and 
impeller maintains radial support and positioning of the impeller towards the front housing. 
The device’s driveline contains motor cables which connect the pump to an external 
controller which sends electrical signals to the dual motor stators in the pump housings 
creating an electromagnetic force that rotates the impeller at speeds ranging from 1,800 to 
4,000 RPM (LaRose et al., 2010). The driveline is also responsible for supplying power to 
the device from an external battery pack or DC power supply connected to the external 
controller. Blood is pulled into the pump through the inflow cannula, pushed to the 
perimeter of the housing by the impeller blades, and propelled through the outflow graft 
by the centrifugal force of the impeller rotation. 
 
FIGURE 6: The HeartWare HVAD with pump inlet to LV apex (A) and outflow graft to the 
ascending aorta (B). VADx (not pictured) has its pump inflow placed in LV apex and its outflow 
cannula tip placed across the aortic valve. 
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        The VADx is an axial flow device that includes a single tubular pump housing 
wrapped around the impeller and vane diffuser. The device incorporates a base pedestal 
which is secured to the ventricular apical sewing ring, the pump housing with rotor 
internals and vane diffuser, a standpipe connecting the pedestal to the pump housing, and 
an outflow cannula (Slaughter et al., 2011; Tamez et al., 2014). The entire assembly is 
positioned inside the LV with the outflow cannula crossing the aortic valve. The VADx’s 
impeller is a single piece of metal allowing it to be magnetized as one unit and has 
hydrodynamic bearings attached to each impeller blade. The standard radial motor stator 
inside the pump housing is able to create rotational speeds from 12,000 to 22,000 RPM and 
provides radial stability for the floating impeller that is partially lifted with the 
hydrodynamic force of blood (Slaughter et al., 2011; Tamez et al., 2014). Blood is pulled 
in from the bottom of the pump housing past the impeller to the vane diffuser which is 
responsible for reducing turbulent flow and improving hydraulic efficiency. Blood exits 
through the outflow cannula which has a trilobar diffuser tip positioned across the aortic 
valve which provides a radial force component to the blood flow and provides radial 
stability to the outflow cannula (Slaughter et al., 2011; Tamez et al., 2014). The length of 
the outflow cannula and standpipe can be adjusted to accommodate various long-axis 
ventricular lengths. 
        The rotational speed of both devices (HVAD and VADx) is regulated by external 
controllers. These controllers adjust the power provided to the motor stators in the pump 
housing or body to set the rotational speed of the impeller. Further information about pump 
operation in both continuous and pulsatile flow modes can be found in the Methods section. 
The devices were asynchronously modulated for 30-days in the healthy bovine model to 
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test the feasibility of the modulation profile as a possible means of controlling phasic 
ventricular volume unloading and providing near-physiologic aortic pulsatility. 
  














A. Study Overview 
        The overall objective of the study was to determine the feasibility of long-term 
asynchronous pump speed modulation of continuous flow ventricular assist devices to 1) 
promote phasic ventricular volume unloading 2) provide greater physiologic aortic 
pulsatility compared to devices operated at constant speed and 3) minimize risk of 
additional blood trauma in a partial VAD support model. A chronic 30-day bovine model 
utilizing healthy, male Jersey calves was selected for this study due to anatomical 
similarities with the human thoracic and cardiovascular systems as described in Monreal 
et al. (Monreal et al., 2014). This study was conducted in accordance with the National 
Institutes of Health Guidelines for the Care and Use of Animals in Research (National 
Research Council (US) Committee for the Update of the Guide for the Care and Use of 
Laboratory Animals, 2011), and all experimental procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) at the University of Louisville. 
B. Experimental Design 
        A chronic bovine model consisting of healthy, male Jersey calves was used to 
investigate the clinical effects of asynchronous speed modulation of two different 
ventricular assist devices: the HeartWare HVAD (n=3 animals) and a proprietary device 
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VADx (n=4 animals). Animals were quarantined for a minimum of 14 days upon arrival 
after which they underwent an implantation procedure for their respective devices. The 
study was carried out for 30 days to investigate any hemodynamic and physiologic changes 
that could be caused by asynchronous modulation. At day-30 post-implant, the animals 
underwent a terminal fluoroscopy procedure then euthanized and transferred to the 
necropsy room for gross dissection. Both devices were tested in continuous flow (CF) and 
pulsatile flow (PF) mode during the implant and day-30 terminal procedures and were 
operated in PF mode during the study period. 
C. Experimental Procedures 
1. Implantation 
        Healthy, male Jersey calves (n=7) weighing 52±3 kg upon arrival were quarantined 
for a minimum of 14 days during which veterinarian assessment were performed, and the 
calves were treated with preventative medicine as follows. Animals implanted with a 
VADx device were administered CORID 20% Soluble Powder (50mg/kg PO) to treat and 
prevent coccidiosis and Panacur (50 mg/kg PO) to remove and control lungworms, stomach 
worms, and intestinal worms. Animals implanted with an HVAD device were administered 
Banamine (2.2 mg/kg IV) for pain management, Excede (6.6 mg/kg SQ) for antibiotic 
treatment, and a probiotic (15 mL PO) to promote healthy bacterial growth. 
        After quarantine, calves were prepared for the implantation procedure as follows. On 
the day prior to surgery, a transdermal 25 or 50 mcg/hr fentanyl patch was applied to the 
animal’s flank for calves weighing less than or equal to 80 kg and greater than 80 kg, 
respectively. A venous blood sample was collected from the jugular vein for baseline 
complete blood count (CBC), biochemical analysis, and coagulation status. The calf was 
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weighed to obtain its pre-fasting weight, and fasting of solid food began 18-20 hours prior 
to the scheduled time of surgery the next morning. Water was withheld 3-4 hours prior to 
surgery. 
        On the morning of surgery, the calf was first weighed to obtain its fasting weight. 
Induction of anesthesia was achieved by intravenous (IV) administration of a ketamine (4 
mg/kg; for dissociative sedation) and diazepam (0.4 mg/kg; for anxiolysis) mix for the 
implantation procedure. The calf was then intubated, and anesthesia was maintained with 
isoflurane at 1-5% with oxygen saturation maintained above 90% for the duration of the 
procedure. An intravenous catheter was placed in a marginal ear vein for administration of 
IV infusions prior to central line placement. IV infusions included carrier fluids of Lactated 
Ringer’s Solution (LRS) or Normosol-R (50-200 mL/hr), amiodarone (1.8 mg/mL at 17-
25 mL/hr) to control arrhythmias, dobutamine (3-5 mcg/kg/min) to control blood pressure, 
and fentanyl (1-10 mcg/kg/hr) for pain management. Electrocardiography (ECG) 
electrodes were sutured onto the skin for lead-II intra- and post-operative monitoring of 
normal cardiac electrical activity, and a pulse oximeter was attached to the ear for intra-
operative monitoring of blood oxygenation levels. Additionally, placement of an orogastric 
(OG) tube was used to decompress the animal’s rumen during surgery. Transesophageal 
echocardiography (TEE; X7-2t probe and iE33 portable ultrasound machine, Phillips, 
Amsterdam, Netherlands) was used for intraoperative cardiac monitoring, data collection, 
and to assist with device placement. 
        In the operating room (for HVAD animals) or fluoroscopy room (for VADx animals), 
sterile technique was used for the implantation procedure. Cefazolin (15-20 mg/kg IV), 
fluxinin meglumine (1.1-2.2 mg/kg IV), and magnesium sulfate (2 g over 1-hour IV) were 
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administered for antibiotic prophylaxis, pain management, and arrhythmia control, 
respectively. For the implantation procedure, the calf was first placed in a right lateral 
recumbency position where the calf’s right neck was cleaned, prepped, and draped in sterile 
fashion, and the right jugular vein was isolated for vascular access port (VAP) insertion 
(9Fr VAP, Norfolk Medical, Skokie, IL). A separate pocket under the subcutaneous tissue 
was made for the VAP which was secured to the underlying fascia and the neck closed 
with 2-0 Vicryl suture. The calf was then repositioned to a left lateral recumbency position 
where the calf’s left neck and chest were cleaned, prepped, and draped in sterile fashion. 
The left jugular vein and carotid artery were accessed via a surgical cutdown. A 7Fr triple 
lumen catheter (Mila International, Florence, KY) was placed in the left jugular vein via 
Seldinger technique to monitor central venous pressure (CVP) and serve as the central 
venous line for IV infusions. A 7Fr introducer sheath with sidearm (Argon, Frisco, TX) 
was placed in the left carotid artery to monitor arterial pressure (ART), to obtain arterial 
blood samples, and for catheter access to the LV. 
        During the implant procedure, succinylcholine (30mg bolus IV) and lidocaine (100mg 
bolus IV) were administered as needed for neuromuscular blockade and cardiac arrhythmia 
control. Intraoperative arterial and venous blood samples were collected every 30 minutes 
for oximetry and chemistry monitoring using a portable blood analysis device (i-STAT 1, 
Abbott, Lake Bluff, IL). Blood samples were also used to measure activated clotting time 
(ACT) with an ACT-II device (Medtronic, Minneapolis, MN) to monitor coagulation 
status. Baseline TEE data, including structural and functional parameters, was collected 
prior to device implantation. Hemodynamic measurements throughout the study were 
recorded with respiratory suspended at a sampling rate of 400 Hz using a PowerLab 16/35 
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module (ADInstruments, Sydney, Australia) connected to the LabChart data acquisition 
software (version 8, ADInstruments). 
        a. HVAD Implantation.  The HVAD device was first prepared by following the 
clinical instructions for use provided by HeartWare. Briefly, the device was submerged in 
a 5% dextrose solution for the initial pre-implant pump test run lasting 30-60 seconds at 
1800 RPM. Afterwards, the outflow graft and strain relief were attached to the device’s 
outflow conduit. De-airing of the pump before implant was achieved by filling the 
assembly with a saline solution. 
        Via a left thoracotomy approach, an approximately 14cm chest incision was made 
over the 5th rib which was subsequently removed. The pericardium was opened anterior to 
the phrenic nerve, and the ascending and descending aorta were exposed. A 24-28 mm flow 
probe (Transonic, Ithaca, NY) was placed on the ascending aorta to measure aortic root 
flow (AoF), and its cable was tunneled through the skin to exit towards the spine. Baseline 
hemodynamics including arterial and central venous pressure and AoF were then recorded 
prior to pump implantation. 
        After baseline hemodynamics were recorded, the pump drive line was tunneled under 
the skin to exit towards the spine. Heparin (10,000 units IV) was administered to maintain 
an ACT greater than 480 seconds. After heparinization, the outflow graft was cut to size 
and anastomosed to the descending aorta using running 3-0 polypropylene suture. The apex 
of the LV was elevated and exposed, and the HVAD apical sewing ring was sutured on 
using 8 interrupted, pledgeted 2-0 Ethibond sutures. The apical coring device was used to 
create a hole for the inflow cannula of the pump which was inserted and secured to the 
apical ring. A 10 mm flow probe (Transonic) was then placed on the VAD outflow graft to 
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measure VAD flow (VADF), and its cable was tunneled through the skin and to exit 
towards the spine. 
        The heart was then lowered, and the device was turned on and operated as described 
in the Pump Operation section. The device was tested in CF and PF modes during which 
hemodynamic and TEE data were recorded with ventilation suspended (at end-exhalation) 
in 30 second epochs. A 28Fr chest tube was placed in the chest cavity then tunneled through 
the skin to exit towards the ventral side of the abdominal region and connected to a water 
seal chest drain. The chest was closed with 0 and 2-0 Vicryl suture. 
        The triple lumen catheter in the left jugular vein and introducer sheath in the left 
carotid artery were exchanged for temporary IV lines prior to transporting the calf to the 
post-operative care room. The left neck was closed using 2-0 Vicryl and 2-0 nylon sutures. 
The temporary lines were secured with 2-0 nylon suture and left in place for an average of 
16 days during the study and then removed once the animals no longer required intravenous 
infusions and medication. After central line removal, the VAP was used to administer IV 
medications as needed as described in the Post-Operative Care section. 
        An intercostal nerve block was performed (Exparel, 2 mg/kg) for pain management 
at the thoracotomy site. Field blocks (Exparel) were performed at the thoracotomy site, all 
exit sites, and both the left and right neck incisions. Finally, the calf was transferred to the 
post-operative care room, weaned from general anesthesia, and extubated. 
        b. VADx Implantation.  In contrast to the HVAD, the VADx device does not need to 
be assembled in the operating room. Preparation of the device in the fluoroscopy room 
began with an initial test run in 5% dextrose solution lasting for at least one minute. A 7Fr 
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Swan-Ganz balloon catheter (Edwards Lifesciences, Irvine, CA) was placed through the 
device’s pedestal and inflated in the pump body for de-airing during implantation. 
        Via a left thoracotomy approach, an approximately 10cm chest incision was made 
over the 5th rib which was subsequently removed. Heparin (10,000 units IV) was 
administered to maintain an ACT greater than 480 seconds. The pump drive line was 
tunneled under the skin to exit towards the spine, and the heart was elevated to expose the 
left ventricular apex. The VADx sewing ring was secured to the apex with interrupted 2-0 
pledgeted Ethibond sutures. The apical coring device was used to create a hole within the 
sewing ring through which the VADx was inserted. The device’s outflow cannula was 
placed across the aortic valve under echocardiographic guidance, with position confirmed 
by fluoroscopy. De-airing of the VADx was achieved through continuous flushing of the 
balloon catheter until the cannula was inside the ventricle. Once the cannula crossed the 
aortic valve, the balloon catheter was deflated and retracted. Retrograde blood flow through 
the base of the pedestal was prevented by an internal one-way valve before the locking pin 
was secured in the pedestal’s cavity. For VADx animals during the implant procedure, 
phenylephrine (100-300 mcg bolus) and protamine (3-4 mg/kg IV) were administered as 
needed to treat hypotension and reverse the effects of heparin. 
        The heart was lowered, and the pump was turned on and operated as described in the 
Pump Operation section. A pressure-volume catheter (Millar, Houston, TX) was 
introduced into the LV through the carotid artery introducer sheath for data collection 
during the implant procedure. The device was tested in CF and PF modes during which 
hemodynamic and echocardiographic data was recorded with ventilation suspended (at 
end-exhalation) in 30 second epochs. The remainder of the procedure was performed as 
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previously described in the HVAD implantation section beginning with placement of the 
chest tube. The pressure-volume catheter was removed before closure of the chest and left 
neck. 
2. Post-operative Care 
        During post-operative care, animals were monitored continuously by veterinary 
personnel. Arterial and venous blood samples were tested for blood oximetry and chemistry 
every hour for the first 48 hours then as needed using the i-STAT device. The ACT-II was 
used to assess ACT every 4 hours until stable then every 6 hours. In addition, arterial blood 
samples were collected to assess CBC (Hemavet 950, Drew Scientific, Miami Lakes, FL) 
and plasma free hemoglobin (pfHb; HemoCue Plasma/Low Hb Photometer, Brea, CA). 
Blood samples were sent to the University of Louisville Hospital for analysis of 
prothrombin time/international normalized ratio (PT/INR). CBC and pfHb tests were 
performed at 1, 8, 16, and 24 hours post-operatively, and PT/INR testing was done daily 
for the first week then twice weekly. Animals were removed from their holding pens 
weekly to be walked on a treadmill for 10-15 minutes for exercise. 
        IV infusions were continued from the implant procedure into the post-operative care 
room. Dobutamine infusion was discontinued before transport from the implant procedure, 
and amiodarone and fentanyl infusions were weaned off 4 days post-implant. Heparin 
infusion (200-300 units/kg IV; 1000 units/mL at 5 mL/hr initially) was administered as 
needed to prevent thrombus formation and maintain an ACT of 200-300 seconds. 
Potassium chloride (in 0.9% saline at 0.5 mEq/kg/hr) and nicardipine (1 mg/mL at 5-20 
mg/hr IV) infusions were administered for the first three days post-implant to treat 
hypokalemia and hypertension respectively. Cefazolin (15-20 mg/kg IV) was administered 
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two to three times daily for 7-14 days post-implant to prevent infection, and flunixin 
meglumine (1.1-2.2 mg/kg IV) was administered 72 hours post-implant for post-operative 
analgesia. Warfarin (5-10 mg titrated in 2.5 mg increments PO) was administered to 
maintain an INR of 1.5-2 times the animal’s baseline through the study duration. Atenolol 
(100 mg IV) was given up to three times daily for the study duration to manage blood 
pressure. 
        All HVAD and VADx devices were operated in PF mode during post-operative care 
according to the device operation sections. Hemodynamic measurements consisting of 
ART, CVP, AoF, and VADF for HVAD animals and ART and CVP only for VADx 
animals were recorded for five-minute epochs at the beginning of every hour for the study 
duration until the arterial and central venous lines were removed. 
3. 30-day Terminal Study and Necropsy 
        At day-30 post-implant, the animals were taken to the fluoroscopy room for their 
terminal procedure. The animals were anesthetized with propofol (4-6 mg/kg IV) via the 
VAP, intubated, and prepped for surgery as previously described for the implant procedure. 
During the terminal procedure, lidocaine (100 mg bolus IV) was administered as needed 
to control cardiac arrhythmias. The animal was placed in a left lateral recumbency where 
a 5 cm incision was made on the left neck over the jugular vein and carotid artery. Both 
vessels were isolated, and a 7Fr triple lumen catheter (Mila International) was placed in the 
jugular vein for pressure monitoring. A 7Fr introducer sheath with sidearm (Argon) was 
placed in the carotid artery for pressure monitoring and ventricular access. A 
ventriculography catheter was passed into the carotid introducer sheath, retrograde across 
the aortic valve, and into the LV. Contrast (Conray-43) ventriculography (INNOVA 3100 
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Fluoroscopy Unit, GE Healthcare, Chicago, IL) was performed to assess ventricular size, 
device flow, and presence of mitral or aortic regurgitation. For animals implanted with an 
HVAD, a pressure-volume catheter (Millar) was passed through the introducer sheath to 
measure left ventricular pressure (LVP) and volume (LVV). For animals implanted with 
the VADx device, a pressure-only catheter was instead used to measure LVP only, and an 
additional pressure catheter was used to measure aortic pressure (AoP). 
        Terminal hemodynamic data for CF, PF, and VAD off conditions were recorded 
including ART, CVP, and LVP and LVV for HVAD animals or LVP and AoP for VADx 
animals. Refer to the Pump Operation section for further details. In addition, terminal TEE 
data was recorded for each condition, and fluoroscopic images were recorded to ensure 
there was no blockage of VAD inflow or outflow grafts/cannulas. All hemodynamic and 
TEE data was collected with ventilation suspended (at end-exhalation) in 30 second 
epochs. After terminal data was recorded, at least 30,000 units of heparin were 
administered intravenously to achieve an ACT greater than 480 seconds to ensure no blood 
clot formation would occur in the body or VAD before dissection. The calf was euthanized 
with an IV bolus of Beuthanasia-D (0.1 mL/lb. IV) and transferred to the necropsy room. 
The veterinarian completed a gross examination, and the pump was carefully removed from 
the calf and examined for any sign of thrombus or malfunction. 
D. Pump Operation 
1. HVAD Operation 
        HVAD devices were controlled by the Clinical Data Acquisition System (CDAS) 
software developed by HeartWare, Inc. The software was able to operate the device in CF 
or PF modes. CF was set by the speed of the internal rotor in RPM. PF was determined by 
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setting the maximum speed in RPM, the percentage drop to the minimum speed, and the 
time for high and low speed duration (setting the duty cycle). When the HVAD devices 
were operated in PF mode, a time of 1.5 seconds was used for the high and low speed 
periods, effectively setting the duty cycle at 3 seconds or 20 beats per minute (BPM). 
Device data including voltage, current, and speed was outputted throughout the entire study 
duration by the CDAS software and recorded simultaneously with hemodynamic data. 
        During the implant and 30-day terminal procedures, three operational modes were 
tested and data recorded: baseline or VAD off, CF mode, and PF mode. For CF, the two 
HVAD devices were set to 2900 RPM and 3200 RPM. For PF, the same devices were set 
to a maximum of 3400 RPM with a 20% speed drop and a maximum of 4000 RPM with a 
40% speed drop respectively. During post-operative care, the devices were operated in PF 
and the CDAS software was set to a maximum speed of 4000 RPM with an average speed 
drop percentage of 37±0.25%. Due to limitations of the CDAS software and hardware 
interface, if a device is disconnected from CDAS it is possible for it to become fixed at the 
RPM set directly before disconnection. In consideration of this limitation, the devices were 
set to CF before the animals were moved for weekly exercise. 
2. VADx Operation 
        VADx devices were controlled by proprietary controller software which was 
developed in order to operate the devices in either CF or PF modes. CF was set by the 
speed of the internal rotor of the device in RPM. In contrast to the HVAD devices, PF was 
determined by setting the maximum speed in RPM, the total drop to minimum speed in 
RPM, and the duration for high and low speed periods. As in HVAD operation, a time of 
1.5 seconds was used for the high and low speed periods. Device data including voltage, 
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current, power, and speed was outputted throughout the entire study duration by the 
controller software and recorded simultaneously with hemodynamic data. 
        Similar to the HVAD devices, three operational modes were tested and data recorded 
during the implant and 30-day terminal procedures: baseline or VAD off, CF mode, and 
PF mode. For CF, three VADx devices were set to 15,000 RPM and one device was set to 
16,000 RPM. For PF, these devices were set to a maximum of 18,000 RPM with a 6000 
RPM speed drop and a maximum of 19,000 RPM with a 6000 RPM speed drop 
respectively. 
        During post-operative care, the VADx devices were set to pulsatile operation and the 
controller software was set to an average maximum of 17510±93 RPM with an average 
speed drop of 5761±85 RPM. Akin to the CDAS software, a limitation of the VADx 
controller software and hardware interface fixes the pump at the RPM setting sent to the 
device directly before it is disconnected from the software. Due to this limitation, the 
VADx devices were set to CF before the animals were moved for weekly exercise. 
E. Experimental Measurements 
        Unfiltered hemodynamic measurements were recorded throughout the study duration 
as previously described at a 400 Hz sampling rate. Briefly, for VADx animals, ART, CVP, 
LVP, and LVV were recorded during implant, ART and CVP were recorded during post-
operative care, and ART, CVP, LVP, and AoP were recorded during the terminal 
procedure. For HVAD animals, ART, CVP, AoF, and VADF were recorded during the 
implant procedure, post-operative care period, and the terminal procedure. LVP and LVV 
were additionally recorded for HVAD animals during the terminal procedure. 
Hemodynamics were used to calculate measures of pulsatility, namely pulse pressure (ΔP), 
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surplus hemodynamic energy (SHE), and arterial impedance (ZART), and determine the 
effects of each VAD operating condition (no VAD/VAD off, CF, PF) on the waveforms. 
A summary of data collection is shown in Figure 7 below. 
 
FIGURE 7: Data collection timeline for the full study duration. HVAD animals (orange) were 
instrumented with flow probes for aortic and VAD flow for the full study duration and with a 
pressure-volume catheter during the terminal study. LVP and LVV were collected for VADx 
animals (grey) during the implantation procedure, and LVP and AoP signals were collected during 
the terminal study. 
        SHE is calculated using the MAP and energy equivalent pressure (EEP) and is a 
measure of the extra energy generated by pulsatile blood flow. EEP is a measure of the 
energy contained in a given volume of fluid pumped through a vessel. The formulas for 
calculating EEP and SHE can be found in Equations 1 and 2, respectively. 
  (1) 
 
  (2) 
ZART is defined as the ratio between the frequency components of the blood pressure and 
flow waveforms and can be used to study the load on the heart due to vessel characteristics 
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such as resistance, compliance, and inductance. Example phase and magnitude graphs for 
ZART in a healthy bovine heart are shown in Figure 8. 
 
FIGURE 8: Example magnitude and phase plots for ZART. Arterial impedance 
(ZART) is the ratio between the frequency components of blood pressure and flow and can 
be split into its magnitude and phase components. The 0th harmonic represents arterial 
resistance of the vasculature. The negative phase in the first few harmonics indicate normal 
vascular compliance. 
        Intrinsic pump parameters including power and speed were recorded as previously 
described. Briefly, the custom HeartWare VAD controller software (CDAS for HVAD 
devices or the proprietary software for VADx devices) outputted pump data to comma 
separated value (CSV) files at set intervals. These data were used to analyze the efficiency 
of the HVAD and VADx devices in CF and PF modes. Additionally, the data were used to 
correlate with trends in hemodynamics collected during the post-operative care period. 
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        Echocardiography was recorded as previously described during the implant and 
terminal procedures. Briefly, TEE was used to capture 3D images of the heart for each test 
condition of the pumps: baseline or VAD off, CF, and PF. These images were used to 
calculate stroke volume (SV), cardiac output (CO), ejection fraction (EF), stroke work, and 
total cardiac work. 
        Blood oximetry and chemistry, CBC, and PT/INR were measured and recorded as 
previously described to guide post-operative care and ensure no abnormal events were 
occurring in individual animals. Blood oximetry results included measurements of lactate, 
pH, total carbon dioxide (TCO2), bicarbonate (HCO3), base excess, oxygen saturation 
(sO2), and partial pressures of carbon dioxide (PCO2) and oxygen (PO2). Blood chemistry 
results included measurements of sodium, potassium, chloride, ionized calcium, TCO2, 
glucose, blood urea nitrogen (BUN), creatinine, hematocrit, and hemoglobin. ACT results 
were used to ensure animals were within range (200-300 seconds) to prevent thrombus 
formation, and pfHb measurements were used to monitor the possibility of thrombus 
formation and results were correlated with device data. 
F. Data Analysis 
        Echocardiographic images comprised of the apical four-chamber view, the apical two-
chamber view, and the short-axis mid-papillary view were analyzed with QLAB software 
(version 10.2, Phillips, Amsterdam, Netherlands) using the 3DQ or 3DQ Advanced 
analysis features. 3DQ Advanced was the preferred method of analysis wherein the end-
diastolic (ED) and end-systolic (ES) frames were selected, and 10 reference points were 
set for each frame to determine the border of the LV. For the ED and ES reference points, 
the septal wall, lateral wall, and apex were chosen on the apical four chamber view, while 
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the anterior and inferior walls were selected on the apical two chamber view. The short-
axis view was used to determine the correct position for the planes of the other two views. 
The software then calculated the border of the LV for each frame of the cardiac cycle and 
determined the ED and ES volumes, SV, and EF. 
        If an advanced 3D image was not captured, 3DQ analysis had to be utilized instead. 
This method utilized selecting points to the left and right of the mitral valve and the apex 
of the LV to determine a rough border for the ED and ES frames. The software then 
calculated the difference in size between the two frames to determine the SV and EF. The 
results of these analyses were then used to calculate cardiac output using the heart rate at 
the time of recording, and stroke work and cardiac work using the MAP at the time of 
recording. Finally, SV, CO, EF, stroke work, and cardiac work were normalized to the 
weight of the animal at the time of recording. 
        Hemodynamic waveforms were exported from the LabChart software into tab 
delimited text files. These data files were loaded into the custom Hemodynamic Estimation 
and Analysis Tool (HEART) Matlab (version R2016, Mathworks, Natick, MA) software 
(Schroeder et al., 2004). The HEART software was used to select individual beats to reduce 
the waveforms into numerical data such as pressure averages and peaks that could then be 
analyzed further. Once the data files were loaded into HEART and the various signals in 
the files identified (e.g. AoP, CVP, AoF, etc.), the beats were picked by determining the 
reference signal (LVP or AoP) and threshold values used in the beat-picking algorithm to 
determine when the next beat occurred. 
        For recordings that did not have a true AoP catheter and signal, the ART signal was 
used to approximate the AoP waveform. Beats were picked on the AoP waveform for all 
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files to simplify later analysis. Once a recording’s beat boundaries were determined, a 
MAT-file was exported from HEART containing all signals and the AoP beat boundaries. 
The MAT-files were trimmed at the beginning and end resulting in uniform 30 second 
epochs for analysis. A custom Matlab script was written to use the beat boundaries to 
calculate beat-to-beat parameters for each signal such as averages and peaks and calculated 
values which used multiple data signals such as SHE and ZART. Calculated parameters 
were outputted for later analysis. 
        Pump data was imported into Excel (Microsoft, Redmond, WA) for preliminary 
organization and analysis. For data recorded during the implant procedure, CF and PF data 
was parsed into 30 second epochs. Mean speed and power was calculated using the average 
of the data, and peak power was calculated as the maximum power in the 30 second period. 
To characterize pump efficiency, the percent change from mean speed during PF operation 
was calculated using the averages of the high and low speed periods to negate overshoot 
caused by the internal pump control system. Percent change of power usage was calculated 
using the percent difference between the mean power of CF and PF mode. 
        Pump data collected during the post-implant period was parsed into 30 second epochs 
and analyzed by a custom Matlab script which determined the average, maximum, and 
minimum speed and the average and peak power for each file. Data were transferred to 
Excel and the percent errors for the speed values from the expected values was calculated. 
        All hemodynamic, echocardiographic, pump, and bloodwork data were transferred to 
GraphPad Prism (version 7, GraphPad, La Jolla, CA) for statistical analysis. Hemodynamic 
and pump data and blood oximetry and chemistry results collected during the post-implant 
period were used to output trend graphs and averages throughout the study. Plasma free 
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hemoglobin results obtained during the post-implant period were additionally used to 
output trend graphs for correlation with hemodynamic and pump results. Statistical 
analysis was performed to determine significant differences between pump operating 
conditions during the implant and terminal procedures. For echocardiographic data, 
Friedman tests, the non-parametric equivalent to repeated measures ANOVA testing, were 
performed to determine significant differences between the three pump operating 
conditions: baseline or VAD off, CF, and PF. For comparisons found to be statistically 
significant, Dunn’s post-test was used to determine which operating conditions produced 
significantly different results. These tests were also used to assess statistical significance 
in HVAD hemodynamic data. For VADx hemodynamic data, some test conditions could 
not be analyzed in repeated measures testing due to complications in data acquisition 
during the surgical procedures. For this reason, unpaired Kruskal-Wallis tests were used to 
assess significant differences between pump operating conditions, and Dunn’s post-test 
was used to determine which specific operating conditions produced significantly different 
results. Data is reported as mean ± standard error of the mean (SEM). A value of p < 0.05 
was considered statistically significant.         
  













A. Study Results 
        This study was carried out to investigate the chronic effects of asynchronous speed 
modulation of rotary blood pumps on phasic ventricular volume unloading and greater 
physiologic aortic pulsatility compared to devices operated at constant speed. Two HVAD 
and four VADx animals achieved the 30-day study endpoint. Due to surgical 
complications, one HVAD animal died intraoperatively. Both HVAD devices maintained 
asynchronous modulation for the full study duration. VADx devices maintained 
asynchronous modulation throughout the study with the exception of two devices that were 
briefly operated in continuous mode for one and two-day periods. Near-physiologic aortic 
pulse pressure (ΔP = systolic AoP – diastolic AoP) of 45 ± 4 mmHg and 46 ± 9 mmHg was 
achieved with asynchronous modulation for HVAD and VADx devices, respectively. In 
addition, stroke volume was acutely reduced by 23% in HVAD animals from continuous 
to pulsatile mode. In VADx animals, stroke volume was reduced by 27% in pulsatile 
operation compared to baseline with no VAD. Plasma-free hemoglobin was maintained 
within normal limits for all animals with the exception of one VADx animal which 
experienced a brief spike in pfHb that resolved itself. 
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B. Operational Device Settings and Intrinsic Pump Parameters 
        Asynchronous, pulsatile modulation was successfully maintained for the full study 
duration for both HVAD devices with average high and low speeds of 4000 RPM and 2500 
RPM respectively. Two out of four VADx devices successfully maintained synchronous 
modulation for the study duration with average high and low speeds of 17,289 RPM and 
11,764 RPM. One VADx device, implanted in animal #5914, was operated at fixed pump 
speed for one day due to high pfHb results and risk of thrombosis. The device was restored 
to asynchronous modulation the next day at its previous settings but later lowered to 
operational high and low speeds of 14,000 RPMs and 9000 RPM, respectively. The other 
VADx device was operated at fixed pump speed for two days due to an unforeseen 
controller malfunction which was corrected to restore asynchronous modulation. 
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FIGURE 9: Average daily post-operative device power usage and operating speed for HVAD 
and VADx devices. VADx device operation was varied throughout the study duration due to 
complications in two of the devices. HVAD and VADx mean power usage was 7.2 ± 0.1 Watts and 
5.3 ± 0.0 Watts, respectively. Peak power was 91% larger than average power use for HVAD 
devices and 67% larger in VADx devices. 
        HVAD devices were operated at a set maximum speed of 4000 RPM (common 
clinical therapeutic setting) with an average set speed drop of 37.3% ± 0.1% throughout 
the post-operative care period. The average power usage throughout this period was 7.2 ± 
0.1 Watts with an average peak power usage of 13.8 ± 0.1 Watts. Peak power usage 
occurred when the devices were ramping up to maximum speed. However, during this 
speed increase, the HVAD briefly spikes in power usage before settling at its peak power. 
This spike was an average of 20.36 ± 0.1 Watts during the post-operative care period. 
VADx devices were operated at an average set maximum speed of 17,263 ± 44 RPM with 
an average set speed drop of 5794 ± 36 RPM throughout the study duration. Average power 
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and peak power usage for VADx devices during the post-operative care period was lower 
than HVAD devices with 5.3 ± 0.0 Watts and 8.8 ± 0.0 Watts respectively. Similar to the 
HVAD devices, VADx peak power occurred during the device ramp up to maximum speed. 
No power spike was observed in VADx devices during the speed increase, but this may be 
due to a low sampling frequency of the controller software. Average post-operative values 
for analyzed intrinsic pump parameters for both devices can be found in Table II presented 
as mean ± SEM (% Error). The percent error for the device speed parameters was calculated 
using the expected values based on the device set points. HVAD devices were found to 
have significantly different (p < 0.0001) power usage during the post-operative care period 
from each other. 
TABLE II 
AVERAGE POST-OPERATIVE INTRINSIC PUMP PARAMETERS 













HVAD 3253 ± 2 (0.56%) 
3961 ± 0 
(0.96%) 
2539 ± 4 
(1.36%) 7.2 ± 0.1 13.8 ± 0.1 
VADX 14602 ± 46 (1.68%) 
17522 ± 45 
(1.50%) 
11752 ± 56 
(2.96%) 5.3 ± 0.0 8.8 ± 0.0 
Average operating parameters during the post-operative care period. Percentages 
indicate the percent error that the result is from the expected value based on pump 
settings. All results expressed as mean ± standard error of the mean. 
 
1. Device Power and Speed Modulation 
        During the implantation procedure, the power usage for both devices and the 
relationship between power and output speed was characterized. The power usage was 
analyzed in CF mode at a set pump speed and with asynchronous modulation in PF mode. 
The set operational speeds for the pulsatile modulation were determined so that the median 
speed matched the CF mode’s set mean pump speed. Power usage between the two modes 
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was compared. One HVAD device experienced a controller malfunction during the testing 
procedure and was unable to be set to pulsatile settings matching the CF mode. In Figure 
10, it can be seen that pulsatile modulation resulted in increased average and peak power 
usage for both devices. One HVAD device could not be included in the implantation results 
due to controller malfunctions. Average and peak power usage was higher in both devices 
when operated in PF mode compared to CF mode during the implantation and terminal 
procedures. At implantation, peak power usage increased by 74% in one HVAD device and 56% 
in the VADx devices compared to CF mode. Power usage was reduced at terminal procedure 
compared to implantation due to lower operational speeds tested. 
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FIGURE 10: Device power usage during continuous and pulsatile flow modes. Asynchronous 
pulsatile modulation resulted in increased power usage for both HVAD and VADx devices with 
peak power usage at implant increasing by 74% in one HVAD device and 56% in the VADx devices 
compared to CF mode. Power usage was reduced at terminal procedure compared to implantation 
due to lower operational speeds tested. Data is presented as the mean +/- SEM. 
        The percent change in power usage that occurs to produce a given speed modulation 
around the median speed was analyzed. It was found that a ±25% speed modulation in one 
HVAD device at implant resulted in a 26% increase in mean power usage and a 74% 
increase in peak power usage compared to CF operation at implantation. An average speed 
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and an average 56% increase in peak power usage (p = 0.026) for the VADx devices. 
Example power and speed waveforms for CF and PF modes for both devices are presented 
in Figure 11. 
 
FIGURE 11: Power usage and speed modulation waveforms. Pulsatile modulation increases 
and decreases rotor speed for set periods of time. In these examples, rotor speed is held at high or 
low speed for 1.5 seconds before alternating. This pulsatile speed modulation results in a pulsatile 
power usage as the device uses more power during its highspeed periods. VADx devices sample 
data less frequently than HVAD devices, explaining the more jagged nature of the waveforms. 
Rotor speed axes differ and represent the normal operating speed of the respective devices.  
C. Left Ventricular Volume Unloading Results 
        Left ventricular (LV) volume unloading was examined through echocardiographic 
data taken during the implantation and terminal procedures including SV, EF, and LVEDV. 
A reduction in SV can indicate an increase in ventricular volume unloading as less volume 
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is pumped by the heart due to the VAD output. However, the SV can be affected by 
variation in the HR, therefore the recordings which had the least variation in HR were used 
for comparison. The HVAD devices reduced SV by an average of 23% from continuous to 
pulsatile operation during the implantation procedure (p = 0.333; 2.5% difference in HR 
with p = 0.667). This shows that asynchronous modulation of the HVAD results in 
increased volume unloading compared to CF mode (current clinical setting), although the 
reduction was not statistically significant. The VADx devices reduced SV by an average 
27% from the preimplant baseline measurement compared to the pulsatile operational 
measurement recorded during the terminal procedure (p = 0.25; 2.6% difference in HR 
with p = 0.875). Cardiac output followed the same trends as SV but was more affected by 
the variation in HR. 
        Typically, in heart failure patients treated with a VAD, LVEDV would decrease as 
the VAD removes blood from the ventricle and decreases preload indicating volume 
unloading. However, as seen in Figure 9, LVEDV increased with VADx pulsatile operation 
during the terminal procedure compared to baseline (22% increase; p = 0.625) but 
decreased in HVAD use (22% decrease; p = 0.333). LVEDV did decrease during pulsatile 
operation compared to CF mode for both devices, indicating that asynchronous modulation 
possibly results in an increased volume unloading compared to CF. In addition, EF would 
be expected to increase in heart failure patients with a VAD as the efficiency of the heart 
increases as the pump reduces the workload. However, EF decreased with VAD usage for 
both devices as seen in Figure 12. Since the animals used in this study were healthy and 
not induced into heart failure, the increase in LVEDV for VADx animals and the decrease 
in EF for both devices would be expected since the device could potentially cause adverse 
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effects as the heart competes for volume. Preload recruitable stroke work (PRSW) is a 
linear index of myocardial contractility. Our study found that PRSW increased with device 
operation. In HVAD devices, PRSW was increased during PF mode compared to CF mode 
at implantation. In VADx devices, PRSW was higher during CF operation compared to PF 
mode at the terminal procedure. 
 
FIGURE 12: Stroke volume (SV), left ventricular end-diastolic volume (LVEDV), ejection 
fraction (EF), and preload recruitable stroke work (PRSW) for VADx and HVAD devices. 
SV was reduced from baseline by both devices and no significant difference was found for either 
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while VADx devices increased LVEDV by 22%. EF was reduced with VAD usage for all animals. 
PRSW increased with device operation but was only increased in PF mode compared to CF mode 
in HVAD devices; no significant differences were found between operating conditions. These 
results were normalized to animal weight in order to remove growth as a factor for any potential 
differences. Preimplant baseline data was collected during implantation procedure before device 
was inserted into the chest. Data is presented as the mean +/- SEM. 
D. Aortic Pulsatility 
1. Aortic Pressure Results 
        Aortic pulsatility was quantified by analyzing changes in hemodynamic pressures and 
flows between the implantation and terminal procedures. AoP was measured for both 
HVAD and VADx animals. The pulse pressure is a measure of the pulsatility of the blood 
flow and pressure waveform through the aorta. During HF, ΔP is diminished as the heart 
can no longer efficiently contract and exert as great a force on the blood. With a CF-VAD 
implanted, ΔP is diminished even further. In this study, it was found that ΔP decreased by 
6.4% (p = ns) in HVAD animals from directly before device implant (52 ± 13 mmHg) to 
pulsatile operation during the terminal procedure (48 ± 7 mmHg). ΔP decreased by 20% (p 
= 0.125) in VADx animals during the same timeframe (49 ± 4 mmHg to 40 ± 2 mmHg). 
However, the ΔP observed during PF operation during the terminal procedure was still 
greater than during CF operation for both HVAD and VADx devices as seen in Figure 13. 
Mean AoP increased from implant to terminal for HVAD animals and decreased for VADx 
animals, but no significant difference was found between testing conditions. 
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FIGURE 13: Mean aortic pressure and pulse pressure for HVAD and VADx animals. Pulse 
pressure decreased from baseline values for both devices during operation but was greater in PF 
mode compared to CF mode. Mean AoP increased in HVAD animals and decreased in VADx 
animals from baseline values. Preimplant baseline data was collected during implantation 
procedure before device was inserted into the chest. Data is presented as the mean +/- SEM. 
        When analyzing the pulse pressure, the overall mean may not take into account the 
asynchronous, pulsatile expansion of the AoP waveform. Examples of this phenomenon 
for both devices can be seen in Figure 14. Both waveforms were captured during the post-
operative care period during pulsatile modulation. When analyzing the waveform at the 
largest drop (circled in black), the more accurate pulse pressure induced by the pulsatile 
modulation can be calculated. Pulsatile operation during these periods for HVAD animals 
resulted in a pulse pressure of 45 ± 4 mmHg and a pulse pressure of 46 ± 9 mmHg for 
VADx animals. 
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FIGURE 14: Aortic pressure waveform expansion due to pulsatile pump operation. 
Sinusoidal, asynchronous effects from pulsatile modulation can be seen in these waveforms. 
Analysis of pulse pressure at the end of one pump cycle can give greater insight into the greater 
pulse pressure that is induced by asynchronous modulation compared to CF or to co-pulse or 
counter-pulsation mechanisms.  
        The rate of change of the aortic waveform (AoP dP/dt) is another measure to give 
insight into the pulsatility of the blood flow. A higher rate of change indicates greater 
energy potential and force that the blood has. In Figure 15, it can be seen that both devices 
had higher ±dP/dt during PF mode compared to CF. VADx devices had higher ±dP/dt at 
the terminal procedure in PF mode compared to baseline. 
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FIGURE 15: Aortic dP/dt for HVAD and VADx animals. HVADs and VADx devices that were 
asynchronously modulated in PF mode resulted in larger ±dP/dt compared to CF mode. VADx 
devices had higher ±dP/dt at the terminal procedure in PF mode compared to baseline. 
2. HVAD-Specific Results 
        Additional hemodynamic parameters were able to be analyzed for the HVAD animals 
to augment pulse pressure data in contrast to VADx animals. Aortic flow was measured 
before the pump’s outflow graft anastomosis to the aorta. The difference between the peak 
minimum and peak maximum flow (ΔQ) can provide greater insight into the pulsatility of 
the actual blood flow. As seen in Figure 16, ΔQ decreased during CF mode in HVAD 
animals as expected and was greater in pulsatile modulation indicating that asynchronous 
modulation did enhance the actual pulsatility of the blood. 
        Aortic pressure and flow was measured in the HVAD animals only, enabling 
calculation of the surplus hemodynamic energy (SHE) and the vascular impedance 
(ZART). The magnitude of ZART expressed in these results indicates the vascular 
resistance component of the impedance at the 0th harmonic. The results demonstrated that 
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compared to CF mode, however no significant difference was found between test 
conditions (p = 0.21). Arterial resistance increased during PF mode compared to CF mode 
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FIGURE 16: SHE, vascular resistance, 
and aortic flow comparison for test 
conditions for HVAD animals. ΔQ 
increased during pulsatile operation 
compared to baseline during implantation 
procedure indicating increased pulsatile 
flow. ΔQ was also markedly greater during 
pulsatile mode compared to CF during both 
procedures indicating larger induced 
pulsatility. SHE increased during pulsatile 
support compared to CF, while arterial 
resistance also increased. Preimplant 
baseline data was collected during 
implantation procedure before device was 
inserted into the chest. Data is presented as 
the mean +/- SEM. 
 58  
3. VADx-Specific Results 
        Asynchronous pulsatile modulation resulted in an increased maximum (+) and 
minimum (-) LV dP/dt at the terminal procedure from baseline by 16% (p = 0.375) and 
75% (p = 0.125) respectively as seen in Figure 17.   
 
FIGURE 17: Left ventricular pressure (LVP) maximum (+dP/dt) and minimum (-dP/dt) rate 
of change for VADx animals. Pulsatile operation resulted in increased maximum and minimum 
rate of change of LVP possibly indicating increased contractility with asynchronous pulsatile 
modulation. No significant differences between testing conditions was observed for either 
parameter (p > 0.088). Preimplant baseline data was collected during implantation procedure before 
device was inserted into the chest. Data is presented as the mean +/- SEM. 
E. Post-Operative Hematologic Data  
        Blood samples were collected periodically throughout the post-operative care period 
to assess animal health and/or the effect of the device on animal health. For all figures in 
this section, each data point represents the average for all animals’ blood collections on 
that day. Only arterial blood samples were statistically analyzed to eliminate error in 
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arterial blood was drawn near the study end for VADx animals. Vertical error bars 
represent the standard error of the mean for the data. Dashed lines represent normal limits 
for bovine animals obtained from Laboratory Animal Medicine (Underwood et al., 2015). 
Baseline data was recorded prior to the day of implant, and post-operative day zero 
represents data collected in the post-operative care room after surgery on the day of 
implant. 
        Complete blood count data was measured to assess overall animal health during the 
post-operative care period. White blood cell (WBC) count was initially elevated during the 
first two days post-implantation as expected due to the surgical stress experienced by the 
animals and then fell to within normal limits for the duration of care. Lymphocytes (LY) 
decreased initially post-implant but returned to normal limits shortly thereafter. 
Neutrophils (NE), red blood cell (RBC) count, platelet count, and hematocrit remained 
within normal limits for the duration of care. Trendline graphs for WBC, LY, NE, RBC 
and platelet count, and hematocrit can be seen in Figure 18. 
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FIGURE 18: Post-operative hematologic biochemistry trends for HVAD and VADx animals. 
WBC was initially elevated post-implant as expected due to the surgical stress experienced by the 
animals and then remained within normal limits for the duration of the study. LY were initially 
decrease post-implant but shortly returned to within normal limits. NE, RBC, platelet count, and 
Hct remained within normal limits throughout the study duration. 
        Prothrombin time (PT)/international normalization ratio (INR) and activated clotting 
time (ACT) testing was done to ensure that anticoagulation was kept to adequate levels to 
prevent pump thrombosis. ACT was kept within the targeted range of 200-300 seconds for 
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both HVAD and VADx animals. INR was initially below the normal range on post-
operative days 1 and 2 and then stayed within the normal range for HVAD animals through 
the duration of care. For VADx animals, INR was within normal limits except for days 18-
26 when it became elevated with an average of 3.8 and 4.6 measured on days 18-22 and 
23-27 respectively. Trendline graphs for these measurements can be seen in Figure 19. 
 
FIGURE 19: Post-operative trends for blood coagulation data. Animals were treated with 
heparin and coumadin during the post-operative care period to target an ACT of 200-300 which 
was maintained throughout the study duration. INR remained within normal limits with the 
exception of VADx animals around post-operative day 25 due to one animal as explained in the 
pfHb section. 
        Blood chemistry and oximetry data was collected to assess end-organ perfusion, 
nutrient transfer, and tissue damage. Serum sodium (Na+), potassium (K+), and ionized 
calcium (Ca2+) were within normal limits for the duration of post-operative care for both 
HVAD and VADx animals. Serum chloride (Cl-) was slightly below the normal range, 
however the 30-day post-operative averages for HVAD and VADx animals were within 
their baseline values. Therefore, blood chemistry did not appear to be affected by pulsatile 
modulation of the VADs. Blood glucose levels were elevated from the normal range, and 
the 30-day averages were 3% and 35% greater than baseline values for HVAD and VADx 
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animals respectively. Normal oxygen saturation was maintained by all animals throughout 
the study duration. pH, pCO2, and bicarbonate (HCO3-) remained within normal limits for 
both devices with the exception of VADx animals near the study end point. pO2 was near 
normal limits except for post-operative day zero for both devices as the animals were on 
100% oxygen following the implantation. One VADx animal was observed to have greatly 
elevated pO2 near the study end-point. Lactate dehydrogenase (LDH) was elevated from 
baseline values in the initial days following implantation as expected. However, LDH 
levels did not begin to fall and return to baseline values until around post-operative day 20. 
The 30-day LDH average was only 56% greater than baseline in VADx animals and 124% 
greater than baseline HVAD animals. The trends for all analyzed blood chemistry and 
oximetry data can be seen in Figures 20 and 21. 
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FIGURE 20: Blood chemistry and oximetry trends for the post-operative care period. Serum Na+, K+, and Ca2+ were within normal limits for 
the duration of post-operative care. Cl- was slightly below the normal range, but post-operative averages for both devices were within 4% of baseline 
values.  
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FIGURE 21: Blood chemistry and oximetry trends for the post-operative care period (continued). LDH was elevated initially post-implantation 
as expected but did not return to baseline levels until post-operative day 20. HCO3-, pH, pO2, and pCO2 remained near normal limits during the 
study duration.
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        Plasma-free hemoglobin (pfHb) was measured throughout the post-operative care 
period to monitor for and assess any signs of hemolysis or thrombosis. Animals implanted 
with an HVAD device did not have pfHb exceeding 10 mg/dL throughout the study 
duration. VADx pfHb results were elevated during post-operative days 15-26 after which 
pfHb returned to baseline levels. This elevated pfHb can be attributed to one animal, 
assigned animal #5914, whom experienced a spike in pfHb at post-operative day 16 which 
remained elevated until post-operative day 25. The post-operative trend for this animal’s 
pfHb results and the average pfHb for both devices can be seen in Figure 22. 
 
FIGURE 22: Post-operative trends for plasma-free hemoglobin (pfHb) and individual 30-day 
results for animal #5914. pfHb was within normal limits (0 to 40 mg/dL) for both devices 
throughout the post-operative care period. However, VADx devices experienced elevated pfHb 
around post-operative days 15-25 due to animal #5914 which appeared to have experienced a 
thrombotic event resulting in a spiked pfHb. 
        While investigating the pfHb spike, it was found that animal #5914 had an associated 
spike in device power usage. The device was subsequently turned to CF mode on post-
operative day 18, then turned back to pulsatile modulation the next day. The operating 
speed for the device was lowered when modulation resumed, then lowered again on post-
operative day 25. Plasma-free hemoglobin results for this animal improved to baseline 
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levels on day 25 and never became elevated afterwards. This data suggests that animal 
#5914 had experienced a thrombotic episode during this period which later subsided. In 
the same vein as pfHb, the elevated LDH levels in VADx animals can be partially attributed 
to animal #5914 whose measured LDH was 185% greater than the average of the remaining 
VADx animals on post-operative day 24. Like pfHb, LDH for animal #5914 eventually 
returned to baseline levels after the device’s operating mode and speed was modified. 
Normal ranges, baseline values, and post-operative averages for all analyzed hematologic 
data are reported in Tables II-VI. 
        The presence of valve regurgitation during the implantation and terminal procedures 
was determined through echocardiographic data analysis. No mitral insufficiency was 
found, and only nominal aortic insufficiency was found during implantation for one HVAD 




NORMAL RANGES, BASELINE VALUES, AND POST-OPERATIVE AVERAGES FOR HEMATOLOGIC DATA 
    INR ACT pfHb pH pCO2** pO2** BEecf HCO3- TCO2 
      (seconds) (mg/dL)   (mmHg) (mmHg) (mEq/L) (mmol/L) (mmol/L) 
Normal Range*  2.5-3.5 200-300 < 40 7.35-7.45 38-46 85-100 (±3) 17-29 21.2-32.2 
HVAD Baseline 1.62 ± 0.04 163 ± 12 5.0 ± 5.0 7.45 ± 0.03 43.7 ± 3.3 34.5 ± 2.5 6.0 ± 0.0 29.9 ± 0.3 31.5 ± 0.5 
  PO Average 2.83 ± 0.20 242 ± 7 4.2 ± 1.0 7.43 ± 0.01 42.1 ± 1.7 108.4 ± 22.1 3.5 ± 1.3 28. ± 1.2 29.1 ± 1.2 
VADx Baseline 2.47 ± 0.35 164 ± 18 7.5 ± 3.2 7.40 ± 0.01 45.6 ± 1.0 30.8 ± 1.5 3.5 ± 0.6 28.3 ± 0.5 29.8 ± 0.5 
  PO Average 3.42 ± 0.12 242 ± 5 16.6 ± 2.8 7.45 ± 0.01 42.1 ± 1.7 122.7 ± 21.3 4.9 ± 1.3 29. ± 1.2 30.1 ± 1.3 
*Normal range for bovine obtained from Laboratory Animal Medicine (Underwood et al., 2015) 
 **Venous blood samples were used for baseline data, explaining the large differences in partial pressures compared to PO averages. 
All results expressed as mean ± standard error of the mean. Post-operative (PO) averages are the means for all arterial blood sample data collected post-implantation 
during the post-operative care period. All blood data results were within normal limits as shown or with minimal deviations from baseline values. BEecf: base excess; 
TCO2: Total CO2. 
TABLE IV 
NORMAL RANGES, BASELINE VALUES, AND POST-OPERATIVE AVERAGES FOR HEMATOLOGIC DATA (CONTINUED) 
    Na+ K+ Cl- Ca2+ Glucose BUN Creatine LDH 
    (mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L) (mg/dl) (U/L) (U/L) 
Normal Range*  132-152 3.9-5.8 97-111 1.0-1.5 45-75 20-30 1-2 692-1445 
HVAD Baseline 140 ± 1 3.80 ± 0.1 95.0 ± 0.0 1.37 ± 0.01 101 ± 1.0 11 ± 1.0 0.45 ± 0.05 2565 ± 395 
  PO Average 140 ± 1 4.05 ± 0.0 98.8 ± 1.5 1.24 ± 0.04 104 ± 5.2 11 ± 2.9 0.52 ± 0.10 7510 ± 1533 
VADx Baseline 139 ± 0.3 4.03 ± 0.1 94.5 ± 0.6 1.33 ± 0.01 78 ± 1.2 11 ± 2.6 0.60 ± 0.06 4427 ± 1048 
  PO Average 137 ± 0.5 4.14 ± 0.1 96.1 ± 0.6 1.31 ± 0.02 105 ± 4.6 10 ± 0.7 0.47 ± 0.03 6296 ± 805 
*Normal range for bovine obtained from Laboratory Animal Medicine (Underwood et al., 2015) 
All results expressed as mean ± standard error of the mean. Post-operative (PO) averages are the means for all arterial blood sample data collected post-implantation 
during the post-operative care period. With the exception of LDH and blood glucose, all blood data results were within normal limits as shown or with minimal 
deviations from baseline values. BUN: blood urea nitrogen. 
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TABLE V 
NORMAL RANGES, BASELINE VALUES, AND POST-OPERATIVE AVERAGES FOR HEMATOLOGIC DATA (CONTINUED) 
    WBC Count NE LY MO EO BA RBC Count 
    (x103/µL) (%) (%) (%) (%) (%) (x106/µL) 
Normal Range*  4-12 15-45 45-75 2-7 2-20 0-2 5-10 
HVAD Baseline 8.07 ± 1.01 34.1 ± 3.9 57.5 ± 0.9 4.1 ± 0.5 4.3 ± 2.6 0.05 ± 0.05 7.30 ± 0.47 
  PO Average 9.53 ± 1.33 27.8 ± 3.4 40.9 ± 6.5 4.8 ± 1.1 26.4 ± 7.9 0.09 ± 0.04 9.04 ± 0.23 
VADx Baseline 11.17 ± 0.64 32.9 ± 4.8 59.5 ± 4.6 5.6 ± 1.0 1.9 ± 0.6 0.08 ± 0.04 8.69 ± 0.24 
  PO Average 11.72 ± 1.05 32.1 ± 2.5 49.5 ± 3.7 5.0 ± 0.6 13.4 ± 3.6 0.12 ± 0.02 8.33 ± 0.25 
*Normal range for bovine obtained from Laboratory Animal Medicine (Underwood et al., 2015) 
All results expressed as mean ± standard error of the mean. Post-operative (PO) averages are the means for all arterial blood sample data collected post-
implantation during the post-operative care period. All blood data results were within normal limits as shown or with minimal deviations from baseline values. 
WBC: white blood cell; NE: neutrophils; LY: Lymphocytes; MO: monocytes; EO: eosinophils; BA: basophils; RBC: red blood cells. 
TABLE VI 
NORMAL RANGES, BASELINE VALUES, AND POST-OPERATIVE AVERAGES FOR HEMATOLOGIC DATA (CONTINUED) 
    Hemoglobin Hematocrit MCV MCH MCHC Platelet Count MPV 
    (g/dL) (% PCV) (fl) (pg) (g/dL) (x103/µL) (fl) 
Normal Range*  8-15 24-46 40-60 11-17 30-36 100-800 4.5-7.5 
HVAD Baseline 8.55 ± 0.05 28.3 ± 1.7 38.9 ± 0.1 11.8 ± 0.8 30.3 ± 2.0 405 ± 146 5.1 ± 0.6 
  PO Average 10.83 ± 0.18 35.4 ± 0.9 39.2 ± 0.1 12.0 ± 0.2 30.6 ± 0.5 272 ± 46 4.7 ± 0.2 
VADx Baseline 10.59 ± 0.25 33.1 ± 1.0 38.1 ± 0.7 12.2 ± 0.3 32.0 ± 0.6 333 ± 7 4.5 ± 0.1 
  PO Average 10.08 ± 0.26 32.3 ± 0.6 39.1 ± 0.9 12.2 ± 0.2 31.2 ± 0.4 300 ± 19 4.7 ± 0.1 
*Normal range for bovine obtained from Laboratory Animal Medicine (Underwood et al., 2015) 
All results expressed as mean ± standard error of the mean. Post-operative (PO) averages are the means for all arterial blood sample data collected post-
implantation during the post-operative care period. All blood data results were within normal limits as shown or with minimal deviations from baseline values. 















A. Overview/Key Findings 
        We have previously reported the feasibility of asynchronous modulation of CF-VADs 
to generate pulsatility and ventricular volume unloading in mock circulatory loop and heart 
failure bovine models for acute durations (Ising et al., 2015; Soucy et al., 2015). To 
investigate long-term effects of asynchronous modulation and build on our previous 
findings, a 30-day chronic, healthy bovine model was used in this study. In addition, 
echocardiographic data was used to calculate LV volumes and examine ventricular volume 
unloading in contrast to pressure-volume catheters placed directly into the ventricle which 
are frequently used. Pump speed modulation in the VADx device has never previously 
been implemented, and this study showed its feasibility and chronic effects. 
        The use of healthy animals in this study created a partial VAD support model that 
showed chronic asynchronous pulsatile modulation of CF-VADs maintained aortic 
pulsatility and reduced stroke volume. LVEDV was reduced in HVAD animals but slightly 
increased in VADx animals. While EF was reduced in all animals, this could have been 
due to limitations in the study design. Minimal increase in power usage and hemolysis 
occurred potentially indicating that asynchronous modulation can be practically 
implemented into current CF-VADs for long-term support. 
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B. Pulsatility 
        Several studies have modulated CF-VAD speeds to examine the effects on aortic 
pulsatility. Bozkurt et al. utilized a mock circulatory loop with an ex-vivo porcine heart 
controlled by a pacemaker to test their novel proportional-integral (PI) controller for device 
outflow in a MicroMed DeBakey VAD (Bozkurt et al., 2014). The PI controller set the 
pump flow rate, the control variable, during the first 1/4th of the cardiac cycle. Pump flow 
rate was measured via a Transonic flow probe located in the pump outflow graft, a feature 
of the DeBakey VAD. They found that this co-pulse synchronized algorithm doubled the 
pulse pressure, pulsatility index, and amplitude of VAD flow in the aorta. Arakawa et al. 
tested their previously developed co-pulse synchronized algorithm for the EVAHEART 
VAD at fixed heart rates in healthy goats and at native heart rates in chronic heart failure 
goats (Arakawa et al., 2016). Their algorithm monitored the ECG and increased pump 
speed for a set amount of time when an R wave was detected. Pulsatile mode produced 
greater pulse pressure and AoP maximum dP/dt than continuous mode and resulted in a 
higher EEP at lower heart rates. While these studies used different pumps and implemented 
co-pulse synchronized algorithms differently, the results are consistent and support the 
findings in our study by showing asynchronous modulation is able to increase pulsatility 
because of intermittent periods of co-pulsation. 
        In a clinical setting, Travis et al. investigated differences in aortic pulsatility between 
CF-VADs and PF-VADs (Travis et al., 2007). Hemodynamic pressure and flow waveforms 
were collected intraoperatively in patients with normal ventricular function (undergoing 
coronary artery bypass) and heart failure patients implanted with either a PF-VAD 
(Thoratec HeartMate XVE or Thoratec IVAD) or CF-VAD (Thoratec HeartMate II or 
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MicroMed DeBakey VAD). In the PF-VAD group, SHE values were restored to baseline 
levels at low VAD speed and augmented at high VAD speed, while SHE was reduced with 
increasing support in the CF-VAD group. Travis et al.’s findings support the results of our 
study that found increased SHE during PF modulation of HVADs compared to CF mode, 
demonstrating this model’s relevance to predicting potential clinical observations. 
C. Volume Unloading 
        A study examining pulsatility and volume unloading in a healthy goat model with a 
speed-modulated EVAHEART VAD by Date et al. found that LV load increased 
significantly during co-pulse modulation compared to counter-pulse modulation (Date et 
al., 2016). The findings of Date et al. suggest the possible benefit of asynchronous 
modulation of CF-VADs in severe heart failure patients. Asynchronous modulation would 
provide intermittent periods of LV loading and unloading which would provide 
simultaneous rest and stimulation for a failing ventricle. This characteristic of 
asynchronous modulation could possibly explain the inconsistent LVEDV effects observed 
between the devices in our study but supports that volume unloading was augmented as 
evidenced by our observed decrease in SV. 
        Kato et al. investigated volume unloading in heart failure patients implanted with 
either a PF-VAD (HeartMate XVE or Thoratec PVAD) or CF-VAD (HeartMate II, 
Duraheart, or DeBakey VAD) and found that pulsatile devices improved LV systolic and 
diastolic function (Kato et al., 2011). In particular, it was found that PF-VADs significantly 
increased EF, while CF-VAD patients did not experience an increased EF. These findings 
do not match the results in this study which observed that EF decreased in all animals 
during the study duration, however it was observed that EF was increased in pulsatile mode 
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in VADx animals. This discrepancy may be attributed to study limitations, most notably 
that healthy animals likely have different cardiac physiology and responses to VAD 
support than the heart failure patients who participated in Kato et al. Our study also found 
that LV +dP/dt was higher in PF mode than CF mode in VADx animals which is consistent 
with Kato et al.’s observation that PF-VADs resulted in greater improvement in and larger 
+dP/dt compared to CF-VADs. This indicates that pulsatile modulation and PF-VADs may 
potentially increase LV contractility leading to greater LV unloading. 
D. Blood Trauma and Power Consumption 
        Additional consideration should be given to the increased power requirements and 
potential blood trauma that could result from CF-VAD speed modulation. While our study 
examined blood trauma via pfHb, other methods of detecting blood trauma such as platelet 
activation and von Willebrand factor (vWf) can provide additional insights into the true 
effects of high shear stress on the blood, however these methods are not routinely used in 
clinical settings (Pirbodaghi, Asgari, et al., 2014). It is possible that pulsatile modulation 
algorithms can affect the hemocompatibility of the device due to different shear stress 
profiles. A recent study by Horobin et al. found that there was no difference in 
hemocompatibility biomarkers such as platelet aggregation and concentrations of vWf, 
ADAMTS13, and pfHb in plasma when comparing pulsatile and continuous flow with an 
HVAD device in a mock circulatory loop utilizing human donor blood (Horobin et al., 
2018). Our study found that five of the six animals with devices operated in asynchronous 
modulation maintained pfHb within clinical range for CF-VAD devices. While our results 
indicate the other animal possibly experienced a brief thrombotic event which was 
resolved, the cause for the event remains unidentified. Our findings and those of Horobin 
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et al. may indicate that chronic pulsatile modulation of CF-VADs does not further 
adversely affect hemocompatibility and hemolysis compared to current clinical practice of 
fixed mean speed CF-VAD use. 
        Our study found that mean device power consumption increased during asynchronous 
modulation compared to CF in HVADs by 26% at implant and 8.7% at the terminal 
procedure and in VADx devices by 6.1% at implant and 9.5% at the terminal procedure, 
and the increase was similar to that found by Soucy et al. which used HVADs in a heart 
failure bovine model (Soucy et al., 2015). Pirbodaghi et al. examined power consumption 
for the HeartMate III (Abbott) in a mock circulatory loop and found that pulsatile mode 
resulted in less than a 2.5% increase in power consumption for any given rotor speed 
(Pirbodaghi, Cotter, et al., 2014). Although the increase in power consumption with a 
HeartMate III was substantially less than that observed in our study or in Soucy et al., the 
pressure gradient in Pirbodaghi et al. was also substantially lower (0 mmHg) than our study 
(about 100 mmHg). These findings suggest that pulsatile modulation may result in 
increased power usage but may not have a major clinical impact on outcomes or power 
supply requirements. 
E. Engineering Considerations 
        Since the animals used in this study were healthy and not induced into heart failure, 
the native cardiac output exceeded device output limits. This created a model that could 
inherently provide only partial VAD support. Full VAD support of the LV was shown to 
be correlated with aortic valve stasis and myocardial atrophy (A. H. Goldstein et al., 2005). 
In response, partial VAD support was proposed to counter these issues since partial 
unloading of the LV allows for aortic valve opening and animation. Previously, partial 
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support has been shown to provide beneficial effects on preload and afterload of the LV in 
a computational fluid dynamics model and an acute bovine experiment (Morley et al., 
2007). Partial VAD support was also shown to decrease myocardial oxygen consumption 
in a chronic heart failure ovine model which can be indicative of myocardial workload 
reduction (A. H. Goldstein et al., 2005). In a clinical setting comparing full and partial 
VAD support, partial support was associated with improved myocardial function and blood 
flow (Maybaum et al., 2002). these results may indicate that partial unloading of the left 
ventricle can improve ventricular function, the effects on the pulsatility of the blood cannot 
easily be examined. With a partial support model, the heart is still ejecting with each beat 
and is contributing to the pulsatility of the blood flow. The influence of modulated CF-
VAD flow on the pulsatility cannot easily be measured, therefore the maintenance of near-
physiologic aortic pulsatility is can be a better comparison between CF and PF modes. Our 
study did find that aortic pulse pressure was higher in PF mode compared to CF mode, 
possibly indicating better maintenance of near-physiologic pulsatility. 
        However, this introduces a concern in the comparison of CF to PF mode. Our study 
fixed CF mode at a set pump speed, then set PF mode in order to match its median speed 
with the speed of CF mode. In a partial support model, the level of cardiac output can differ 
between animals in this configuration and therefore comparisons between CF and PF mode 
may be limited. Another configuration for CF and PF mode comparisons can be created by 
changing each mode’s settings to produce the same fixed level of cardiac support. This 
configuration would give greater meaning to comparisons made between PF and CF mode 
including power and pulsatility measurements. However, when briefly testing the output 
of both operational modes in HVAD animals, we observed that setting the median speed 
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of the PF mode to the fixed CF mode speed resulted in the same level of VAD support in 
both operational modes. Unfortunately, the VADx devices were unable to be tested in this 
way during this study due to the lack of flow instrumentation. Further experimentation 
using a mock circulatory loop and volume output normalized to time could determine if 
this configuration results in similar VAD support levels with the VADx device. 
        When testing the devices by fixing the desired support level between operational 
modes, the effects of further modifying the amplitude and frequency of asynchronous 
modulation can be examined. Pulsatility of the blood flow can be enhanced by increasing 
the difference between the high and low speeds. Mean pressure can be adjusted by shifting 
this window up or down the device’s operational speed range. LV unloading can be 
adjusted during PF mode with the same level of VAD support as CF mode by adjusting the 
frequency of the asynchronous modulation. Previously, we found that lower frequencies 
(higher duty cycles) of asynchronous modulation resulted in higher pulse pressure and 
lower LV external work (Soucy et al., 2015). This effect may be due to the longer periods 
of partial loading and unloading of the ventricle. However, this also may suggest that 
synchronized modulation may provide better outcomes in partial support models due to the 
ability to specifically target LV unloading since the heart can induce native pulsatility 
through its own contribution to the blood flow. 
        Finally, the VAD’s outflow graft anastomosis to the aorta can affect the flow pattern 
and pulsatility of the blood. The HVAD outflow graft is anastomosed end-to-side on the 
descending aorta which can create areas of turbulent blood flow at the junction. Depending 
on the angle of the anastomosis, blood flow can recirculate around the junction from the 
VAD’s flow and enter back into the outflow graft or travel in either direction (with or 
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against native blood flow) in the aorta. This turbulence can potentially reduce the pulsatility 
of the blood flow in the aorta as the VAD flow detracts from native cardiac output. The 
VADx device does not experience this phenomenon since it’s outflow cannula is positioned 
in line with native cardiac output in the aorta. However, the cannulation of the VADx 
across the aortic valve has its own concerns. For instance, the repeated opening and closing 
of the aortic valve around the outflow cannula with partial VAD support may cause 
bruising of the valve leaflets. Another consideration in our study model was that the 
cannula size had to be chosen to ensure that the tip did not retract into the LV when the 
animal grew. 
F. Limitations 
        This study has several potential limitations. First, the calves used in this study were 
chosen to be small (about 50 kg), however the HVAD animals had a longer period between 
arrival and implantation compared to the VADx animals explaining their larger starting 
weight. Second, we used healthy calves as opposed to a clinically relevant heart failure 
model that would have differences in cardiac output and vascular compliance of the 
animals. Third, our study design with calves is not conducive for chronic instrumentation 
with indwelling catheters; therefore, the majority of our data was recorded during the 
implantation and terminal procedures. Fourth, since implantation of the VADx device only 
requires a mini thoracotomy, the need for a large cut to insert the device and other 
instrumentation is negated. Therefore, since we could not acquire blood flow data in these 
animals, other measures of pulsatility such as SHE and EEP could not be calculated. Fifth, 
volumetric analysis was limited to the accuracy of the QLAB software in tracking of the 
ventricular wall. Finally, while all effort was made to standardize care, individual 
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circumstances with each animal could have affected which medications they received, their 

















        Our results suggest that asynchronous pulsatile modulation is an effective means to 
accomplish phasic ventricular volume unloading and greater physiologic aortic pulsatility 
while minimizing the risk of additional blood trauma. This study showed that it is feasible 
to asynchronously modulate the rotor speed of CF-VADs for long-term support to maintain 
near-physiologic pulsatility and reduce stroke volume with minimal hemolysis and 
increased power usage. The potential clinical impact of these findings is that chronic 
asynchronous modulation may be able to provide favorable conditions which could 
potentially reduce adverse event rates associated with CF-VAD use. Further studies using 
heart failure animals as the experimental platform may lead to a greater understanding of 
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